5-HT receptor ligands and uses thereof

ABSTRACT

Compounds of Formula (IC) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT 2  receptors in animals are described herein                  
 
.

This application is a divisional of U.S. patent application Ser. No. 10/156,884 filed on May 28, 2002 now U.S. Pat. No. 6,825,198 which claims the benefit of U.S. Provisional Ser. No. 60/299,953 filed Jun. 21, 2001 both of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

The present invention relates to pyrimidine compounds that act as 5-HT receptor ligands, in particular 5-HT_(2c)receptor ligands, and their uses in the prevention or treatment of diseases linked to the activation of 5-HT_(2c) receptors in animals.

BACKGROUND

Receptors for serotonin (5-hydroxytryptamine, 5-HT) are an important class of G protein-coupled receptors. Serotonin is thought to play a role in processes related to learning and memory, sleep, thermoregulation, mood, motor activity, pain, sexual and aggressive behaviors, appetite, neurodegenerative regulation, and biological rhythms. As expected, serotonin is linked to pathophysiological conditions such as anxiety, depression, obsessive-compulsive disorders, schizophrenia, suicide, autism, migraine, emesis, alcoholism and neurodegenerative disorders.

The serotonin receptors are currently classified into seven subfamilies (5-HT₁ through 5-HT₇). See, Hoyer, D., et al., “VII International Union of Pharmacology classification of receptors for 5-hydroxytryptamine”, Pharmacol. Rev., 56, 157–203 (1994). The subfamilies have been further divided into subtypes. For example, the 5-HT₂ receptor is currently divided into three subtypes: 5-HT_(2a), 5-HT_(2b) and 5-HT_(2c). The three subtypes of 5-HT₂ receptors are linked to phospholipase C with the generation of two second messengers, diacylglycerol (which activates protein kinase C) and inositol trisphosphate (which releases intracellular stores of Ca²⁺). The 5-HT_(2c) receptors have a very high density in the choroid plexus, an epithelial tissue that is the primary site of cerebrospinal fluid production. See, Sanders-Bush, E. and S. E. Mayer, “5-Hydroxytryptamine (Serotonin) Receptor agonists and Antagonists”, Goodman & Gilman's The Pharmacological Basis of Therapeutics, Chapter 11, 9^(th) Ed., McGraw-Hill, New York, N.Y. (1996).

Julius, et al., isolated and characterized the 5-HT_(2c) receptor and later reported that transgenic mice lacking the 5-HT_(2c) receptor exhibit seizures and an eating disorder resulting in increased consumption of food (see, U.S. Pat. Nos. 4,985,352 and 5,698,766, respectively). Consequently, compounds selective for the 5-HT_(2c) receptor may provide useful therapies for the treatment of seizure and eating disorders without the side effects typically associated with nonselectivity of the ligand.

Several compounds have been proposed as 5-HT_(2c) receptor agonists or antagonists for use in the treatment of obesity and other related diseases associated with decreased neurotransmission of serotonin in mammals. See, e.g., EP 863136 (azetidine and pyrrolidine derivatives); EP 657426 (tricyclic pyrrole derivatives); EP 655440 (substituted 1-aminoethyl indoles); EP 572863 (pyrazinoindole derivatives); WO98/030548 (aminoalkylindazole compounds); WO 98/56768 (tricyclic pyrrole and pyrazole derivatives); WO 99/43647 (azetidine and pyrrolidine derivatives); WO 99/58490 (aryl-hydronaphthalenalkanamine derivatives); WO 00/12475 (indoline derivatives); WO 00/12482 (indazole derivatives); WO 00/12502 (pyrroloquinoline derivatives); WO 00/12510 (pyrroloindole, pyridoindole and azepinoindole derivatives); WO 00/28993 (naphthylacetylpiperazine derivatives); WO 00/44737 (aminoalkylbenzofuran derivatives); and WO 00/76984 (2,3-disubstituted pyrazines).

The non-selectivity of ligands for the various 5-HT receptors remains a challenge. It is suspected that the non-selectivity of some ligands contributes to various adverse side effects such as hallucinations and cardiovascular complications. Therefore, there remains a need for 5-HT_(2c) selective receptor ligands.

SUMMARY

The present invention provides compounds of Formula (IA) which are useful as 5-HT₂ receptor ligands (in particular, 5-HT_(2a) and 5-HT_(2c) receptor ligands).

wherein

X and Y are CR and Z is N, or X is N and Y and Z are CR, where R for each occurrence is hydrogen, halogen, (C₁–C₄)alkyl, amino, or (C₁–C₄)alkylamino;

W is oxy, thio, amino, (C₁–C₄)alkylamino, or acetylamino;

at least one of R^(1a), R^(1b), R^(1d), and R^(1e) is independently selected from the group consisting of halogen, nitro, amino, cyano, —C(O)NH₂, (C₁–C₄)alkyl, halo-substituted(C₁–C₄)alkyl, (C₁–C₄) alkoxy, and halo-substituted(C₁–C₄)alkoxy, or R^(1a) and R^(1b) taken together form a five- or six-membered, aromatic or partially or fully saturated fused ring, or R^(1a) taken together with R^(2a) or R^(2b) forms a five- or six-membered, fully saturated fused ring;

R^(1c) is hydrogen;

R^(2a) and R^(2b) are each independently hydrogen, (C₁–C₄)alkyl, partially or fully saturated (C₃–C₆)cycloalkyl, or one of which taken together with R^(1a) forms a five- or six-membered, fully saturated fused ring;

n is 0, 1, or 2;

R^(3a) and R^(3b) are each independently hydrogen, (C₁–C₄)alkyl, or (C₁–C₄)alkyl substituted with hydroxy, fluoro, or (C₁–C₄)alkoxy;

R⁴ is hydrogen, hydroxy, (C₁–C₄)alkyl, (C₁–C₄)alkyl substituted with hydroxy or cyano, (C₁–C₄)alkylcarbonyl, (C₁–C₄)alkoxy, (C₁–C₄)alkoxycarbonyl, (C₃–C₄)alkenyl, or an amino-protecting group;

a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

Preferred compounds of Formula (IA) are those where X and Y are CR and Z is N, or X is N and Y and Z are CR, where R is hydrogen, chloro, fluoro, or methyl;

-   -   (i) R^(1a) is halogen, (C₁–C₄)alkyl, trifluoromethyl, methoxy,         or trifluoromethoxy, and R^(1b), R^(1d) and R^(1e) are each         hydrogen,     -   (ii) R^(1b) is halogen, methyl, or methoxy and R^(1a), R^(1d)         and R^(1e) are each hydrogen,     -   (iii) R^(1a) and R^(1b) are each independently halogen or methyl         and R^(1d) and R^(1e) are each hydrogen,     -   (iv) R^(1b) and R^(1d) are each independently halogen or methyl         and R^(1a) and R^(1e) are each hydrogen,     -   (v) R^(1a) and R^(1d) are each independently halogen or methyl         and R^(1b) and R^(1e) are each hydrogen,     -   (vi) R^(1a) and R^(1e) are each independently halogen or methyl         and R^(1b) and R^(1d) are each hydrogen, or     -   (vii) R^(1a), R^(1b) and R^(1d) are each independently halogen         or methyl and R^(1e) is hydrogen;         W is oxy or amino; n is 1; R^(2a) and R^(2b) are each         independently methyl or hydrogen; R^(3a) and R^(3b) are each         independently hydrogen or (C₁–C₂)alkyl (preferably (2R)-methyl         or (2R)-ethyl); and R⁴ is hydrogen or (C₁–C₄)alkyl; a nitrogen         oxide thereof, a prodrug of the compound or the nitrogen oxide;         a pharmaceutically acceptable salt of the compound, the nitrogen         oxide, or the prodrug, or a solvate or hydrate of the compound,         the nitrogen oxide, the prodrug, or the salt.

When Z is N, then X is preferably CH; Y is CR, where R for each occurrence is hydrogen or methyl; (i) R^(1a) is halogen, (C₁–C₄)alkyl, trifluoromethyl, methoxy, or trifluoromethoxy, and R^(1b), R^(1d) and R^(1e) are each hydrogen, (ii) R^(1b) is halogen, methyl, or methoxy and R^(1a), R^(1d) and R^(1e) are each hydrogen, (iii) R^(1a) and R^(1b) are each independently halogen or methyl and R^(1d) and R^(1e) are each hydrogen, (iv) R^(1b) and R^(1d) are each independently halogen or methyl and R^(1a) and R^(1e) are each hydrogen, (v) R^(1a) and R^(1d) are each independently halogen or methyl and R^(1b) and R^(1e) are each hydrogen, (vi) R^(1a) and R^(1e) are each independently halogen or methyl and R^(1b) and R^(1d) are each hydrogen, or (vii) R^(1a), R^(1b) and R^(1d) are each independently halogen or methyl and R^(1e) is hydrogen; W is oxy or amino; n is 1; R^(2a) and R^(2b) are each independently methyl or hydrogen; and R^(3a) is hydrogen, (2R)-methyl, or (2R)-ethyl; and R^(3b) is hydrogen; and R⁴ is hydrogen or (C₁–C₄)alkyl; a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

When X is N, then Y is preferably CR, where R is hydrogen or methyl; Z is CH; (i) R^(1a) is halogen, (C₁–C₄)alkyl, trifluoromethyl, methoxy or trifluoromethoxy and R^(1b), R^(1d) and R^(1e) are each hydrogen; (ii) R^(1b) is halogen, methyl, or methoxy and R^(1a), R^(1d) and R^(1e) are each hydrogen, (iii) R^(1b) and R^(1d) are each independently halogen or methyl and R^(1a) and R^(1e) are each hydrogen, or (iv) R^(1a) and R^(1d) are each independently halogen or methyl and R^(1b) and R^(1e) are each hydrogen; W is amino; n is 1; R²a and R^(2b) are each independently methyl or hydrogen; R^(3a) is hydrogen, (2R)-methyl, or (2R)-ethyl; and R^(3b) is hydrogen; and R⁴ is hydrogen or (C₁–C₄)alkyl; a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

Non-limiting examples of preferred compounds of Formula (IA) include;

2-(2-chloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(3-fluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(3-chloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(3-chloro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(3-methoxy-benzyloxy)-4-piperazin-1-yl-pyrimidine,

(3-chloro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine,

(3-chloro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

(3-fluoro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

(3-fluoro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine,

2-[1-(3-fluoro-phenyl)-ethoxy]-4-methyl-6-piperazin-1-yl-pyrimidine,

2-[1-(3-fluoro-phenyl)-ethoxy]-4-piperazin-1-yl-pyrimidine,

2-[1-(2-chloro-phenyl)-ethoxy]-4-piperazin-1-yl-pyrimidine,

2-[1-(3-chloro-phenyl)-ethoxy]-4-piperazin-1-yl-pyrimidine,

2-[1-(3-chloro-phenyl)-ethoxy]-4-methyl-6-piperazin-1-yl-pyrimidine,

2-(2,3-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-difluoro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(2,5-dichloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-dichloro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(3,5-dichloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(3,5-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine, and

4-piperazin-1-yl-2-(2,3,5-trifluoro-benzyloxy)-pyrimidine,

a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

Preferred salts include 2-(2-chloro-benzyloxy)-4-piperazin-1-yl-pyrimidine, hydrochloride; 2-(3-fluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine, hydrochloride; 2-(3-chloro-benzyloxy)-4-piperazin-1-yl-pyrimidine, hydrochloride; 2-(3-chloro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine, hydrochloride; (3-chloro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine, hydrochloride; (3-chloro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine, hydrochloride; (3-fluoro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine, hydrochloride; (3-fluoro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine, fumarate; 2-(2,3-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine, hydrochloride; 2-(2,5-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine, hydrochloride; 2-(2,5-dichloro-benzyloxy)-4-piperazin-1-yl-pyrimidine, hydrochloride; 2-(3,5-dichloro-benzyloxy)-4-piperazin-1-yl-pyrimidine, hydrochloride; and 2-(3,5-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine, hydrochloride.

Non-limiting examples of more preferred compounds of Formula (1A) include;

2-(3-chloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(3-chloro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

(3-chloro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

(3-chloro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine,

(3-fluoro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

(3-fluoro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine,

2-(2,3-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-difluoro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(2,5-dichloro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(3,5-dichloro-benzyloxy)-4-piperazin-1-yl-pyrimidine, and

4-piperazin-1-yl-2-(2,3,5-trifluoro-benzyloxy)-pyrimidine;

a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

In yet another embodiment of the present invention, compounds of Formula (IC) are provided.

wherein

X and Y are CR and Z is N, or X is N and Y and Z are CR, where R for each occurrence is hydrogen, halogen, (C₁–C₄)alkyl, amino, or (C₁–C₄)alkylamino;

W is oxy, thio, amino, (C₁–C₄)alkylamino, or acetylamino;

Q is a heteroaryl group selected from the group consisting of pyridin-2-yl, pyridin-3-yl, furan-3-yl, furan-2-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, pyrrol-2-yl, pyrrol-3-yl, pyrazol-3-yl, quinolin-2-yl, quinolin-3-yl, isoquinolin-3-yl, benzofuran-2-yl, benzofuran-3-yl, isobenzofuran-3-yl, benzothiophen-2-yl, benzothiophen-3-yl, indol-2-yl, indol-3-yl, 2H-imidazol-2-yl, oxazol-2-yl, isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-triazol-3-yl, and 1,2,4-oxathiazol-3-yl, where said heteroaryl group is optionally substituted with one to three substituents independently selected from halo, (C₁–C₄)alkyl or (C₁–C₄)alkyoxy;

R^(2a) and R^(2b) are each independently hydrogen, (C₁–C₄)alkyl, or partially or fully saturated (C₃–C₆)cycloalkyl;

R^(3a) and R^(3b) are each independently hydrogen, (C₁–C₄)alkyl, or (C₁–C₄)alkyl substituted with hydroxy, fluoro, or (C₁–C₄)alkoxy;

R⁴ is hydrogen, hydroxy, (C₁–C₄)alkyl, (C₁–C₄)alkyl substituted with hydroxy or cyano, (C₁–C₄)alkylcarbonyl, (C₁–C₄)alkoxy, (C₁–C₄)alkoxycarbonyl, (C₃–C₄)alkenyl, or an amino-protecting group;

a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

Non-limiting examples of preferred compounds of Formula (IC) include: 4-piperazin-1-yl-2-(pyridin-2-ylmethoxy)-pyrimidine, 2-(6-methyl-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine, and 2-(6-chloro-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine; a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

Non-limiting examples of more preferred compounds of Formula (1C) include 2-(6-methyl-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine and 2-(6-chloro-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine; a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

Some of the compounds described herein contain at least one chiral center; consequently, those skilled in the art will appreciate that all stereoisomers (e.g., enantiomers and diasteroisomers) of the compounds illustrated and discussed herein are within the scope of the present invention. In addition, tautomeric forms of the compounds are also within the scope of the present invention.

In another embodiment of the present invention, a pharmaceutical composition is provided that comprises (1) a compound of Formula (IA) or (1C), a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt, and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

In yet another embodiment of the present invention, a method for treating 5-HT₂ (preferably, 5-HT_(2c)) receptor-mediated diseases, conditions, or disorders in an animal that includes the step of administering to the animal a therapeutically effective amount of a compound of Formula (IB)

wherein

X and Y are CR and Z is N, or X is N and Y and Z are CR, where R for each occurrence is hydrogen, halogen, (C₁–C₄)alkyl, amino, or (C₁–C₄)alkylamino;

W is oxy, thio, amino, (C₁–C₄)alkylamino, or acetylamino;

R^(1a), R^(1b), R^(1c), R^(1d) and R^(1e) are each independently hydrogen, halogen, nitro, cyano, amino, (C₁–C₄)alkyl, halo-substituted (C₁–C₄)alkyl, (C₁–C₄)alkoxy, halo-substituted (C₁–C₄)alkoxy, —C(O)NH₂, R^(1a) and R^(1b) taken together form a five- or six-membered, aromatic or partially or fully saturated fused ring, or R^(1a) taken together with R^(2a) or R^(2b) forms a five- or six-membered, fully saturated, fused ring;

R^(2a) and R^(2b) are each independently hydrogen, (C₁–C₄)alkyl, partially or fully saturated (C₃–C₆)cycloalkyl, or one of which taken together with R^(1a) forms a five- or six-membered, fully saturated fused ring;

n is 0, 1, or 2;

R^(3a) and R^(3b) are each independently hydrogen, (C₁–C₄)alkyl, (C₁–C₄)alkyl substituted with hydroxy, fluoro, or (C₁–C₄)alkoxy;

R⁴ is hydrogen, hydroxy, (C₁–C₄)alkyl, (C₁–C₄)alkyl substituted with hydroxy or cyano, (C₁–C₄)alkylcarbonyl, (C₁–C₄)alkoxy, (C₁–C₄)alkoxycarbonyl, or (C₃–C₄)alkenyl;

a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt. Alternatively, compounds having Formula (IC) above may also be used as the therapeutic agent.

Non-limiting examples of preferred compounds of Formula (IB) include 2-benzyloxy-4-methyl-6-piperazin-1-yl-pyrimidine,

2-benzyloxy-4-piperazin-1-yl-pyrimidine,

4-benzyloxy-2-piperazin-1-yl-pyrimidine,

benzyl-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

benzyl-(2-piperazin-1-yl-pyrimidin-4-yl)-amine,

2-(3-fluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(3-chloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(3-chloro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(3-methoxy-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2-chloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

(3-chloro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine,

(3-chloro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

(3-fluoro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

(3-fluoro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine,

2-[1-(3-fluoro-phenyl)-ethoxy]-4-methyl-6-piperazin-1-yl-pyrimidine,

2-[1-(3-fluoro-phenyl)-ethoxy]-4-piperazin-1-yl-pyrimidine,

2-[1-(2-chloro-phenyl)-ethoxy]-4-piperazin-1-yl-pyrimidine,

2-[1-(3-chloro-phenyl)-ethoxy]-4-piperazin-1-yl-pyrimidine,

2-[1-(3-chloro-phenyl)-ethoxy]-4-methyl-6-piperazin-1-yl-pyrimidine,

2-(2,3-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-difluoro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(2,5-dichloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-dichloro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(3,5-dichloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(3,5-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine, and

4-piperazin-1-yl-2-(2,3,5-trifluoro-benzyloxy)-pyrimidine;

a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

Non-limiting examples of more preferred compounds include

2-benzyloxy-4-methyl-6-piperazin-1-yl-pyrimidine,

benzyl-(2-piperazin-1-yl-pyrimidin-4-yl)-amine,

benzyl-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

4-benzyloxy-2-piperazin-1-yl-pyrimidine,

2-benzyloxy-4-piperazin-1-yl-pyrimidine,

2-(3-chloro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(3-chloro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

(3-chloro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

(3-chloro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine,

(3-fluoro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine,

(3-fluoro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl )-amine,

2-(2,3-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine,

2-(2,5-difluoro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(2,5-dichloro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine,

2-(3,5-dichloro-benzyloxy)-4-piperazin-1-yl-pyrimidine, and

4-piperazin-1-yl-2-(2,3,5-trifluoro-benzyloxy)-pyrimidine;

a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

Compounds of the present invention may be administered in combination with other pharmaceutical agents, such as apo-B/MTP inhibitors, MCR-4 agonists, CCK-A agonists, monoamine reuptake inhibitors, sympathomimetic agents, β₃ adrenergic receptor agonists, dopamine agonists, melanocyte-stimulating hormone receptor analogs, cannabinoid 1 receptor antagonists, melanin concentrating hormone antagonists, leptins, leptin analogs, leptin receptor agonists, galanin antagonists, lipase inhibitors, bombesin agonists, neuropeptide-Y antagonists, thyromimetic agents, dehydroepiandrosterone or analogs thereof, glucocorticoid receptor agonists or antagonists, orexin receptor antagonists, urocortin binding protein antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors, AGRPs (human agouti-related proteins), ghrelin receptor antagonists, histamine 3 receptor antagonists or reverse agonists, neuromedin U receptor agonists, and the like.

The combination therapy may be administered as (a) a single pharmaceutical composition which comprises a compound of the present invention, at least one additional pharmaceutical agent described above and a pharmaceutically acceptable excipient, diluent, or carrier; or (b) two separate pharmaceutical compositions comprising (i) a first composition comprising a compound of Formula (IA), (IC), or (IB) and a pharmaceutically acceptable excipient, diluent, or carrier, and (ii) a second composition comprising at least one additional pharmaceutical agent described above and a pharmaceutically acceptable excipient, diluent, or carrier. The pharmaceutical compositions may be administered simultaneously or sequentially and in any order.

In yet another aspect of the present invention, a pharmaceutical kit is provided for use by a consumer to treat or prevent 5-HT₂ receptor-mediated diseases, conditions, or disorders in an animal (preferably, 5-HT_(2c) receptor-mediated diseases, conditions or disorders). The kit comprises a) a suitable dosage form comprising a compound of the present invention; and b) instructions describing a method of using the dosage form to treat or prevent a 5-HT₂ receptor-mediated disease, condition, or disorder.

In yet another embodiment of the present invention is a pharmaceutical kit comprising: a) a first dosage form comprising (i) a compound of the present invention and (ii) a pharmaceutically acceptable carrier, excipient or diluent; b) a second dosage form comprising (i) an additional pharmaceutical agent described above, and (ii) a pharmaceutically acceptable carrier, excipient or diluent; and c) a container.

Another aspect of the present invention is a method for treating female sexual dysfunction (FSD) comprising the step of administering to a female in need thereof a therapeutically effective amount of a compound of the present invention. The method may further include the administration of one or more additional active agents for treating FSD. The additional active agents may be selected from the group consisting of (1) as estrogen receptor modulators, estrogen agonists, estrogen antagonists or combinations thereof; (2) testosterone replacement agent, testosternone (Tostrelle), dihydrotestosterone, dehydroepiandrosterone (DHEA), a testosterone implant, or combinations thereof; (3) estrogen, a combination of estrogen and medroxyprogesterone or medroxyprogesterone acetate (MPA), or estrogen and methyl testosterone hormone replacement therapy agent; (4) one or more dopaminergic agents; (5) one or more of an NPY (neuropeptide Y) inhibitor; (6) one or more of a melanocortin receptor agonist or modulator or melanocortin enhancer; (7) one or more of an NEP inhibitor; (8) one or more of a PDE inhibitor; and (9) one or more of a bombesin receptor antagonist or modulator. The FSD treatments include female sexual arousal disorder (FSAD), female orgasmic disorder (FOD), hypoactive sexual desire disorder (HSDD), or sexual pain disorder.

In another embodiment of the present invention, a method is provided for treating male erectile dysfunction (MED) comprising the step of administering to a male in need thereof a therapeutically effective amount of a compound of the present invention.

Another aspect of the present invention is a method of increasing lean meat content in an edible animal comprising the step of administering to the edible animal a lean meat increasing amount of a compound of the present invention or a composition comprising the compound of the present invention. The compounds of the present invention may also be administered to the edible animal in combination with any one of the additional pharmaceutical agents described above.

Definitions

As used herein, the term “alkyl” refers to a hydrocarbon radical of the general formula C_(n)H_(2n+1). The alkane radical may be straight or branched. For example, the term “(C₁–C₄)alkyl” refers to a monovalent, straight, or branched aliphatic group containing 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, and other constitutional isomers containing 1 to 4 carbon atoms (including stereoisomers). The alkane radical may be unsubstituted or substituted with one or more substituents. For example, a “halo-substituted alkyl” refers to an alkyl group substituted with one or more halogen atoms (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, perfluoroethyl, chloromethyl, bromomethyl, and the like). Similarly, the alkyl portion of an alkoxy, alkylamino, dialkylamino, or alkylthio group has the same meaning as alkyl defined above and the halo-substituted alkyl portion of a halo-substituted alkoxy, alkyl amino, dialkylamino or alkylthio group has the same meaning as halo-substituted alkyl defined above.

The term “partially or fully saturated cycloalkyl” refers to nonaromatic rings that are either partially or fully hydrogenated. For example, partially or fully saturated (C₃–C₆)cycloalkyl includes groups such as cyclopropyl, cyclopropenyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclpentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, and the like. Unless specified otherwise, the term “fused ring” refers to partially or fully saturated as well as aromatic carbocyclic and heterocyclic ring systems. Preferably, the heterocyclic ring contains 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur (optionally oxidized to the corresponding sulfone or sulfoxide). Non-limiting examples of fused ring systems include naphthalene, indane, indene, isoindene, benzofuran, isobenzofuran, benzo[b]thiophene, benzo[c]thiophene, indole, 3H-indole, 1H-isoindole, indazole, indoxazine, benzoxazole, anthranil, tetralin, 2H-1-benzopyran, quinoline, isoquinoline, cinnoline, quinazoline, 2H-1,3-benzoxazine, 2H-1,4-benzoxazine, 1H-2,3-benzoxazine, 4H-2,1-benzoxazine, 2H-1,2-benzoxazine, 4H-1,4-benzoxazine, and the like.

The term “heteroaryl” refers to aromatic monocyclic or bicyclic ring systems containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. The heteroaryl group may be unsubstituted or substituted with 1 to 3 substituents. Preferred substituents include halo (Br, Cl, I, or F), (C₁–C₄) alkyl, and (C₁–C₄) alkoxy. Suitable heteroaryl groups include pyridin-2-yl, pyridin-3-yl, furan-3-yl, furan-2-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, pyrrol-2-yl, pyrrol-3-yl, pyrazol-3-yl, quinolin-2-yl, quinolin-3-yl, isoquinolin-3-yl, benzofuran-2-yl, benzofuran-3-yl, isobenzofuran-3-yl, benzothiophen-2-yl, benzothiophen-3-yl, indol-2-yl, indol-3-yl, 2H-imidazol-2-yl, oxazol-2-yl, isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-triazol-3-yl, 1,2,4-oxathiazol-3-yl, and the like.

The term “substituted” means that a hydrogen atom on a molecule has been replaced with a different atom or molecule. The atom or molecule replacing the hydrogen atom is denoted as a “substituent.” The term substituted specifically envisions and allows for substitutions that are common in the art. However, it is generally understood by those skilled in the art that the substituents should be selected so as to not adversely affect the pharmacological characteristics of the compound or adversely interfere with the use of the medicament.

The term “nitrogen oxide” or “N-oxide” refers to the oxidation of at least one of the nitrogens in the pyrimidine or pyrazine ring of the compounds of Formula (IA), (IB) or (IC)(e.g., mono- or di-oxide). The nitrogen mono-oxides may exist as a single positional isomer or a mixture of positional isomers (e.g., a mixture of 1-N-oxide and 3-N-oxide pyrimidines or a mixture of 1-N-oxide and 4-N-oxide pyrazines).

The term “protecting group” or “Pg” refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound. For example, an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include acetyl and silyl. A “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include —CH₂CH₂SO₂Ph, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, nitroethyl and the like. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.

The term “ligand” refers to a compound that binds to a receptor. As used herein, the ligand may possess partial or full agonist or antagonist activity.

The phrase “therapeutically effective amount” means an amount of a compound of the present invention that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.

The term “animal” refers to humans, companion animals (e.g., dogs, cats and horses), food-source animals, zoo animals, marine animals, birds and other similar animal species. “Edible animals” refers to food-source animals such as cows, pigs, sheep and poultry.

The phrase “pharmaceutically acceptable” indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.

The terms “treating”, “treat”, or “treatment” embrace both preventative, i.e., prophylactic, and palliative treatment.

The term “compounds of the present invention” (unless specifically identified otherwise) refer to compounds of Formulae (IA), (IC) and (IB), nitrogen oxides thereof, prodrugs of the compounds or nitrogen oxides, pharmaceutically acceptable salts of the compounds, nitrogen oxides, and/or prodrugs, and hydrates or solvates of the compounds, nitrogen oxides, salts, and/or prodrugs, as well as, all stereoisomers (including diastereoisomers and enantiomers), tautomers and isotopically labeled compounds.

DETAILED DESCRIPTION

The present invention provides a method for treating or preventing 5-HT₂ receptor-mediated diseases, conditions, or disorders by administering compounds of Formula (IB) which act as 5-HT₂ receptor ligands (preferably, 5-HT_(2c) and/or 5-HT_(2a) receptor ligands).

wherein

X and Y are CR and Z is N, or X is N and Y and Z are CR, where R for each occurrence is hydrogen, halogen, (C₁–C₄)alkyl, amino, or (C₁–C₄)alkylamino;

W is oxy, thio, amino, (C₁–C₄)alkylamino, or acetylamino;

R^(1a), R^(1b), R^(1c), R^(1d) and R^(1e) are each independently hydrogen, halogen, nitro, cyano, amino, —C(O)N H₂, (C₁–C₄)alkyl, halo-substituted (C₁–C₄)alkyl, (C₁–C₄)alkoxy, halo-substituted (C₁–C₄)alkoxy, R^(1a) and R^(1b) taken together form a five- or six-membered, aromatic or partially or fully saturated fused ring, or R^(1a) taken together with R^(2a) or R^(2b) forms a five- or six-membered, fully saturated fused ring;

R^(2a) and R^(2b) are each independently hydrogen, (C₁–C₄)alkyl, partially or fully saturated (C₃–C₆)cycloalkyl, or one of which taken together with R^(1a) forms a five- or six-membered, fully saturated fused ring;

n is 0, 1, or 2 (preferably 1 or 2);

R^(3a) and R^(3b) are each independently hydrogen, (C₁–C₄)alkyl, or (C₁–C₄)alkyl substituted with hydroxy, fluoro, or (C₁–C₄)alkoxy;

R⁴ is hydrogen, hydroxy, (C₁–C₄)alkyl, (C₁–C₄)alkyl substituted with hydroxy or cyano, (C₁–C₄)alkylcarbonyl, (C₁–C₄)alkoxy, (C₁–C₆)alkoxycarbonyl, or (C₃–C₄)alkenyl;

a nitrogen oxide thereof, a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug, or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug, or the salt.

Compounds of the present invention may be synthesized by synthetic routes that include processes analogous to those known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1–19, Wiley, N.Y. (1967–1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).

For illustrative purposes, the reaction schemes depicted below provide potential routes for synthesizing the compounds of the present invention as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds. Although specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art. For example, a sulfide linkage (i.e., W=S) can be easily oxidized to its corresponding sulfinyl or sulfonyl group (i.e., W=SO or SO₂) using common oxidation procedures (e.g., oxidation with m-chloroperbenzoic acid).

In the preparation of compounds of the present invention, protection of remote functionality (e.g., primary or secondary amine) of intermediates may be necessary. The need for such protection will vary depending on the nature of the remote functionality and the conditions of the preparation methods. Suitable amino-protecting groups (NH-Pg) include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethyleneoxycarbonyl (Fmoc). The need for such protection is readily determined by one skilled in the art. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.

Scheme I illustrates the preparation of compounds of the present invention where W is O, S, amino or (C₁–C₄)alkylamino.

Reaction of the di-halogen substituted heteroaryl compound of Formula II with a compound of Formula III (R⁴ may optionally be an amino-protecting group) in a suitable solvent (e.g., ethanol, t-butanol, n-butanol, toluene, dioxane, THF, DMF, or acetonitrile) in the presence of a suitable base (e.g., sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide (NaOH), potassium hydroxide, 1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU), triethylamine (TEA) or pyridine) at about 25° C. to about 200° C. for about 1 to about 168 hours gives intermediate IV. Treatment of intermediate IV with an excess of the appropriate amine in a solvent (e.g., EtOH, t-BuOH, dioxane, THF or DMF) in the presence of a suitable base (e.g., sodium carbonate, potassium carbonate, cesium carbonate, NaOH, sodium hydride, DBU, TEA or pyridine) at about 25° C. to about 200° C. for about 1 to about 7 days produces intermediate V wherein W is an amino linking group or a (C₁–C₄)alkyl substituted amino linking group. Suitable amines include benzylamine, 3-chlorobenzyl amine, 3-fluorobenzyl amine, and the like.

Alternatively, intermediate IV may be reacted with an anion of an appropriate alcohol or thiol in a solvent (e.g., THF, toluene, dioxane, DMF, benzene, or a mixture of benzene and water) with or without a catalyst such as 18-crown-6 at about 25° C. to about 200° C. for about 1 to about 48 hours to yield compounds of formula V wherein W is O or S. The anion may be obtained by treatment of the corresponding alcohol or thiol with a base (e.g., potassium carbonate, sodium hydride, sodium hydroxide, potassium hydroxide, potassium t-butoxide, or sodium metal) in an inert solvent (e.g., toluene, dioxane, DMF, THF, or benzene) at about 25° C. to about 200° C. for about 1 to about 24 hours.

Suitable alcohols include benzyl alcohol, α-phenethyl alcohol, β-phenethyl alcohol, 3-fluoro-benzyl alcohol, 3-chloro-benzyl alcohol, 3-methoxybenzyl alcohol, 2-chlorobenzyl alcohol, 3-fluoro-α-phenethyl alcohol, 2-chloro-α-phenethyl alcohol, 3-chloro-α-phenethyl alcohol, 2,5-difluorobenzyl alcohol, 2,5-dichlorobenzyl alcohol, 3,5-difluorobenzyl alcohol, 3,5-dichlorobenzyl alcohol, 2-hydroxymethylpyridine, 2-hydroxymethyl-6-chloro-pyridine, 2-hydroxymethyl-6-methyl-pyridine, and the like.

Suitable thiols include, α-toluenethiol, (2-methylphenyl)methanethiol, 3-(trifluoromethyl)-α-toluenethiol, 2-chloro-α-toluenethiol, (3-methylphenyl)-methanethiol, 2-chloro-6-fluorobenzylmercaptan, o-fluorobenzyl mercaptan, m-chlorobenzyl mercaptan, 2,4,6-trimethylbenzyl mercaptan, and the like.

The sulfide linkage can be oxidized to the corresponding sulfinyl or sulfonyl using standard oxidation procedures well known to those skilled in the art.

When R⁴ is an amino-protecting group, intermediate V is deprotected to give the amine VI. For example, a BOC protected amine may be deprotected by treatment with trifluoroacetic acid (TFA) in CH₂Cl₂. The secondary amine VI can then be alkylated to the amine VII by methods well known to those skilled in the art. A preferred method is reductive alkylation. Generally, reductive alkylation reactions convert intermediate VI into a Schiff base by reaction with the desired aldehyde or ketone in a polar solvent at a temperature from about 10° C. to about 140° C. for about 2 to about 24 hours in the presence of 3 Å molecular sieves. Typically, an equivalent or a slight excess of the aldehyde or ketone is added to the amine. Suitable polar solvents include methylene chloride, 1,2-dichloroethane, dimethylsulfoxide, dimethylformamide, alcohols (e.g., methanol or ethanol), or mixtures thereof. A preferred solvent is methanol. In the same reaction vessel, the imine is then reduced to the tertiary amine in the presence of a reducing agent at a temperature from about 0° C. to about 10° C. and then warmed to a temperature from about 20° C. to about 40° C. for about 30 minutes to about 2 hours. Suitable reducing agents include pyridine•borane complex and metal borohydrides, such as sodium borohydride, sodium triacetoxy borohydride and sodium cyanoborohydride. Suitable aldehydes or ketones include paraformaldehyde, acetaldehyde, acetone and the like.

Alternatively, the amine VI may be acylated or converted to a carbamate according to methods well known to those skilled in the art.

Compounds of the present invention where W is an amino linking group (NH) or alkylamino linking group can also be prepared by reductive alkylation of an amino group attached to the pyrimidine or pyrazine ring as illustrated in Scheme II below. The synthetic procedures are analogous to those described above for the reductive alkylation of intermediate VI in Scheme I.

The compound of Formula VIII can be converted to the benzyl amine XI by methods well known in the art. A preferred method is reductive alkylation as described earlier in Scheme I where a Schiff base is formed with intermediate IX and then reduced with an appropriate reducing agent. Suitable aldehydes and ketones (i.e., compound of Formula IX) include 3-chlorobenzaldehyde, 3-fluorobenzaldehyde, m-chloroacetophenone, m-chloropropiophenone, o-chloroacetophenone, 2-fluorobenzaldehyde, 2-chlorobenzaldehyde, 2,6-dichlorobenzaldehyde, 2,5-dichloroacetophenone, 2-chloro-5-methylacetophenone, 2,5-difluoroacetophenone, 2,5-difluoropropiophenone, 2,3-dichlorobenzaldehyde, 2,3-difluorobenzaldehyde, 2,5-difluorobenzaldehyde, 2-chloro-5-fluoroacetophenone, 5-chloro-2-methoxybenzaldehyde, 2-fluoro-5-methoxybenzaldehyde, 2,5-dichlorobenzaldehyde, 3,5-dichlorobenzaldehyde, 3,5-dichloroacetophenone, 3,5-difluorobenzaldehyde, 2,3,5-trifluorobenzaldehyde, 2,3,5-trifluoroacetophenone, 2,3,5-trifluoropropiophenone, 2,3,5-trichlorobenzaldehyde, 2,3,6-trifluorobenzaldehyde, and the like. Treatment of the resultant compound of Formula X with piperazine III in a suitable solvent (e.g., ethanol, t-butanol, n-butanol, toluene, dioxane, THF, DMF or acetonitrile) in the presence of a suitable base (e.g., sodium carbonate, potassium carbonate, sodium hydroxide, TEA, DBU or pyridine) at about 25° to about 200° C. for about 1 day to about seven days gives compounds of the Formula XI.

Conventional methods and/or techniques of separation and purification known to one of ordinary skill in the art can be used to isolate the compounds of the present invention, as well as the various intermediates related thereto. Such techniques will be well-known to one of ordinary skill in the art and may include, for example, all types of chromatography (high pressure liquid chromatography (HPLC), column chromatography using common adsorbents such as silica gel, and thin-layer chromatography), recrystallization, and differential (i.e., liquid-liquid) extraction techniques.

The compounds of the present invention may be isolated and used per se or in the form of its pharmaceutically acceptable salt, solvate and/or hydrate. The term “salts” refers to inorganic and organic salts of a compound of the present invention. These salts can be prepared in situ during the final isolation and purification of a compound, or by separately reacting the compound, N-oxide, or prodrug with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, hydroiodide, sulfate, bisulfate, nitrate, acetate, trifluoroacetate, oxalate, besylate, palmitiate, pamoate, malonate, stearate, laurate, malate, borate, benzoate, lactate, phosphate, hexafluorophosphate, benzene sulfonate, tosylate, formate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. See, e.g., Berge, et al., J. Pharm. Sci., 66, 1–19 (1977).

The term “nitrogen oxide” or “N-oxide” refers to the oxidation of at least one of the nitrogen atoms in the pyrimidine or pyrazine ring. Oxidation of aromatic nitrogens is well known in the art. Typical oxidizing agents include reagents such as hydrogen peroxide, trifluoroperacetic acid, m-chloroperbenzoic acid and the like. In general, the oxidation is accomplished in an inert solvent (e.g., methylene chloride or chloroform). The position of the N-oxidation may vary depending upon the steric hinderance from substituents on an adjacent carbon atom. The N-oxide or mixture of N-oxides can be isolated or separated using conventional procedures such as liquid chromatography and/or selective crystallization.

The term “prodrug” means a compound that is transformed in vivo to yield a compound of Formula (IA, IB or IC) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms, such as through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

For example, if a compound of the present invention contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C₁–C₈)alkyl, (C₂–C₁ ₂)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C₁–C₂)alkylamino(C₂–C₃)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C₁–C₂)alkyl, N,N-di(C₁–C₂)alkylcarbamoyl-(C₁–C₂)alkyl and piperidino-, pyrrolidino- or morpholino(C₂–C₃)alkyl.

Similarly, if a compound of the present invention contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C₁–C₆)alkanoyloxymethyl, 1-((C₁–C₆)alkanoyloxy)ethyl, 1-methyl-1-((C₁–C₆)alkanoyloxy)ethyl, (C₁–C₆)alkoxycarbonyloxymethyl, N-(C₁–C₆)alkoxycarbonylaminomethyl, succinoyl, (C₁–C₆)alkanoyl, α-amino(C₁–C₄)alkanoyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)₂, —P(O)(O(C₁–C₆)alkyl)₂ or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).

If a compound of the present invention incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as R-carbonyl, RO-carbonyl, NRR′-carbonyl where R and R′ are each independently (C₁–C₁ ₁₀)alkyl, (C₃–C₇)cycloalkyl, benzyl, or R-carbonyl is a natural α-aminoacyl or natural α-aminoacyl-natural α-aminoacyl, —C(OH)C(O)OY′ wherein Y′ is H, (C₁–C₆)alkyl or benzyl, —C(OY₀)Y₁ wherein Y₀ is (C₁–C₄) alkyl and Y₁ is (C₁–C₆)alkyl, carboxy(C₁–C₆)alkyl, amino(C₁–C₄)alkyl or mono-N- or di-N,N-(C₁–C₆)alkylaminoalkyl, —C(Y₂)Y₃ wherein Y₂ is H or methyl and Y₃ is mono-N- or di-N,N-(C₁–C₆)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yl.

The compounds of the present invention may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the present invention as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of the present invention incorporates a double bond or a fused ring, both the cis- and trans- forms, as well as mixtures, are embraced within the scope of the invention. Both the single positional isomers and mixture of positional isomers resulting from the N-oxidation of the pyrimidine and pyrazine rings are also within the scope of the present invention.

Diastereomeric mixtures can be separated into their individual diastereoisomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereoisomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers. Also, some of the compounds of the present invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of a chiral HPLC column.

The compounds of the present invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.

It is also possible that the compounds of the present invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. For example, all of the tautomeric forms of the imidazole moiety are included in the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.

The present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, and ³⁶Cl, respectively.

Certain isotopically-labeled compounds of the present invention (e.g., those labeled with ³H and ¹⁴C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., ³H) and carbon-14 (i.e., ¹⁴C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., ²H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

Compounds of the present invention are useful 5-HT₂ partial agonists or antagonists (preferably 5-HT_(2a) or 5-HT_(2c) partial agonists or antagonists); therefore, another embodiment of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention and a pharmaceutically acceptable excipient, diluent or carrier.

A typical formulation is prepared by mixing a compound of the present invention and a carrier, diluent or excipient. Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and/or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like. The particular carrier, diluent or excipient used will depend upon the means and purpose for which the compound of the present invention is being applied. Solvents are generally selected based on solvents recognized by persons skilled in the art as safe (GRAS) to be administered to a mammal. In general, safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycols (e.g., PEG400, PEG300), etc. and mixtures thereof. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

The formulations may be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (i.e., compound of the present invention or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent)) is dissolved in a suitable solvent in the presence of one or more of the excipients described above. The compound of the present invention is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to give the patient an elegant and easily handleable product.

The pharmaceutical composition (or formulation) for application may be packaged in a variety of ways depending upon the method used for administering the drug. Generally, an article for distribution includes a container having deposited therein the pharmaceutical formulation in an appropriate form. Suitable containers are well-known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like. The container may also include a tamper-proof assemblage to prevent indiscreet access to the contents of the package. In addition, the container has deposited thereon a label that describes the contents of the container. The label may also include appropriate warnings.

The present invention further provides methods of treating 5-HT₂ receptor-mediated diseases, conditions, or disorders in an animal in need of such treatment that include administering to the animal a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition comprising an effective amount of a compound of the present invention and a pharmaceutically acceptable excipient, diluent, or carrier. The method is particularly useful for treating 5-HT_(2c) receptor-mediated diseases, conditions, or disorders. Preferably, the compounds of the present invention act as a partial agonist at the 5-HT_(2c) receptor site. More preferably, the compounds of the present invention act as a partial agonist the 5-HT_(2c) receptor site and as an antagonist at the 5-HT_(2a) receptor site.

Preferably, the 5-HT₂ receptor-mediated disease, condition, or disorder is selected from the group consisting of weight loss (e.g., reduction in calorie intake), obesity, bulimia, premenstrual syndrome or late luteal phase syndrome, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, migraine, alcoholism, tobacco abuse, panic disorder, anxiety, post-traumatic syndrome, memory loss, dementia of aging, social phobia, attention deficit hyperactivity disorder, disruptive behavior disorders, impulse control disorders, borderline personality disorder, obsessive compulsive disorder, chronic fatigue syndrome, sexual dysfunction in males (e.g., premature ejaculation and erectile difficulty), sexual dysfunction in females, anorexia nervosa, disorders of sleep (e.g., sleep apnea), autism, seizure disorders, epilepsy, mutism, spinal cord injury, damage of the central nervous system (e.g., trauma, stroke, neurodegenerative diseases or toxic or infective CNS diseases (e.g., encephalitis or meningitis)), cardiovascular disorders (e.g., thrombosis), gastrointestinal disorders (e.g., dysfunction of gastrointestinal motility), diabetes insipidus, and type II diabetes. Accordingly, the compounds of the present invention described herein are useful in treating 5-HT₂ receptor-mediated diseases, conditions, or disorders. Consequently, the compounds of the present invention (including the compositions and processes used therein) may be used in the manufacture of a medicament for the therapeutic applications described herein.

The compounds of the present invention can be administered to a patient at dosage levels in the range of from about 0.7 mg to about 7,000 mg per day. For a normal adult human having a body weight of about 70 kg, a dosage in the range of from about 0.01 mg to about 100 mg per kilogram body weight is typically sufficient. However, some variability in the general dosage range may be required depending upon the age and weight of the subject being treated, the intended route of administration, the particular compound being administered and the like. The determination of dosage ranges and optimal dosages for a particular patient is well within the ability of one of ordinary skill in the art having the benefit of the instant disclosure. It is also noted that the compounds of the present invention can be used in sustained release, controlled release, and delayed release formulations, which forms are also well known to one of ordinary skill in the art.

The compounds of this invention may also be used in conjunction with other pharmaceutical agents for the treatment of the diseases/conditions described herein. Therefore, methods of treatment that include administering compounds of the present invention in combination with other pharmaceutical agents are also provided. Suitable pharmaceutical agents that may be used in combination with the compounds of the present invention include anti-obesity agents such as apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-B/MTP) inhibitors, MCR-4 agonists, cholecystokinin-A (CCK-A) agonists, monoamine reuptake inhibitors (such as sibutramine), sympathomimetic agents, β₃ adrenergic receptor agonists, dopamine agonists (such as bromocriptine), melanocyte-stimulating hormone receptor analogs, cannabinoid 1 receptor antagonists, melanin concentrating hormone antagonists, leptins (the OB protein), leptin analogs, leptin receptor agonists, galanin antagonists, lipase inhibitors (such as tetrahydrolipstatin, i.e. orlistat), anorectic agents (such as a bombesin agonist), Neuropeptide-Y antagonists, thyromimetic agents, dehydroepiandrosterone or an analog thereof, glucocorticoid receptor agonists or antagonists, orexin receptor antagonists, urocortin binding protein antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors (such as Axokine™ available from Regeneron Pharmaceuticals, Inc., Tarrytown, N.Y. and Procter & Gamble Company, Cincinnati, Ohio), human agouti-related proteins (AGRP), ghrelin receptor antagonists, histamine 3 receptor antagonists or reverse agonists, and neuromedin U receptor agonists. Other anti-obesity agents, including the preferred agents set forth hereinbelow, are well known, or will be readily apparent in light of the instant disclosure, to one of ordinary skill in the art.

Especially preferred are anti-obesity agents selected from the group consisting of orlistat, sibutramine, bromocriptine, ephedrine, leptin, and pseudoephedrine. Preferably, compounds of the present invention and combination therapies are administered in conjunction with exercise and a sensible diet.

Representative anti-obesity agents for use in the combinations, pharmaceutical compositions, and methods of the invention can be prepared using methods known to one of ordinary skill in the art, for example, sibutramine can be prepared as described in U.S. Pat. No. 4,929,629; bromocriptine can be prepared as described in U.S. Pat. Nos. 3,752,814 and 3,752,888; and orlistat can be prepared as described in U.S. Pat. Nos. 5,274,143; 5,420,305; 5,540,917; and 5,643,874. All of the above recited U.S. patents are incorporated herein by reference.

The dosage of the additional pharmaceutical agent (e.g., anti-obesity agent) will also be generally dependent upon a number of factors including the health of the subject being treated, the extent of treatment desired, the nature and kind of concurrent therapy, if any, and the frequency of treatment and the nature of the effect desired. In general, the dosage range of an anti-obesity agent is in the range of from about 0.001 mg to about 100 mg per kilogram body weight of the individual per day, preferably from about 0.1 mg to about 10 mg per kilogram body weight of the individual per day. However, some variability in the general dosage range may also be required depending upon the age and weight of the subject being treated, the intended route of administration, the particular anti-obesity agent being administered and the like. The determination of dosage ranges and optimal dosages for a particular patient is also well within the ability of one of ordinary skill in the art having the benefit of the instant disclosure.

In another embodiment of the present invention, the compounds of the present invention are useful in the treatment of sexual dysfunction. Sexual dysfunction (SD) is a significant clinical problem, which can affect both males and females. The causes of SD may be both organic as well as psychological. Organic aspects of SD are typically caused by underlying vascular diseases, such as those associated with hypertension or diabetes mellitus, by prescription medication and/or by psychiatric disease such as depression. Physiological factors include fear, performance anxiety and interpersonal conflict. SD impairs sexual performance, diminishes self-esteem and disrupts personal relationships thereby inducing personal distress. In the clinic, SD disorders have been divided into female sexual dysfunction (FSD) disorders and male sexual dysfunction (MSD) disorders (Melman et al 1999). FSD is best defined as the difficulty or inability of a woman to find satisfaction in sexual expression. Male sexual dysfunction (MSD) is generally associated with erectile dysfunction, also known as male erectile dysfunction (MED) (Benet et al 1994—Male Erectile dysfunction assessment and treatment options. Comp. Ther. 20: 669–673.).

The compounds of the invention are particularly beneficial for the prophylaxis and/or treatment of sexual dysfunction in the male (e.g. male erectile dysfunction—MED) and in the female—female sexual dysfunction (FSD), e.g. female sexual arousal disorder (FSAD).

It is known that some individuals can suffer from male erectile dysfunction (MED). MED is defined as: “the inability to achieve and/or maintain a penile erection for satisfactory sexual performance” (NIH Consensus Development Panel on Impotence, 1993)”.

It has been estimated that the prevalence of erectile dysfunction (ED) of all degrees (minimal, moderate and complete impotence) is 52% in men 40 to 70 years old, with higher rates in those older than 70 (Melman, A. & Gingell, J. C. (1999). The epidemiology and pathophysiology of erectile dysfunction. J. Urology 161: 5–11). The condition has a significant negative impact on the quality of life of the patient and their partner, often resulting in increased anxiety and tension which leads to depression and low self esteem. Whereas two decades ago, MED was primarily considered to be a psychological disorder (Benet, A. E. et al (1994), Male erectile dysfunction assessment and treatment options. Comp. Ther. 20: 669–673), it is now known that for the majority of patients there is an underlying organic cause. As a result, much progress has been made in identifying the mechanism of normal penile erection and the pathophysiology of MED.

Penile erection is a haemodynamic event which is dependent upon the balance of contraction and relaxation of the corpus cavernosal smooth muscle and vasculature of the penis (Lerner, S. E. et al (1993). A review of erectile dysfunction: new insights and more questions. J. Urology 149: 1246–1255). Corpus cavernosal smooth muscle is also referred to herein as corporal smooth muscle or in the plural sense corpus cavernosa. Relaxation of the corpus cavernosal smooth muscle leads to an increased blood flow into the trabecular spaces of the corpus cavernosa, causing them to expand against the surrounding tunica and compress the draining veins. This produces a vast elevation in blood pressure which results in an erection (Naylor, A. M. (1998). Endogenous neurotransmitters mediating penile erection. Br. J. Urology 81: 424–431).

The changes that occur during the erectile process are complex and require a high degree of coordinated control involving the peripheral and central nervous systems, and the endocrine system (Naylor, 1998). Corporal smooth muscle contraction is modulated by sympathetic noradrenergic innervation via activation of postsynaptic α₁ adrenoceptors. MED may be associated with an increase in the endogenous smooth muscle tone of the corpus cavernosum. However, the process of corporal smooth muscle relaxation is mediated partly by non-adrenergic, non-cholinergic (NANC) neurotransmission. There are a number of other NANC neurotransmitters found in the penis, other than NO, such as calcitonin gene related peptide (CGRP) and vasoactive intestinal peptide (VIP). The main relaxing factor responsible for mediating this relaxation is nitric oxide (NO), which is synthesized from L-arginine by nitric oxide synthase (NOS) (Taub, H. C. et al (1993). Relationship between contraction and relaxation in human and rabbit corpus cavernosum. Urology 42: 698–704). It is thought that reducing corporal smooth muscle tone may aid NO to induce relaxation of the corpus cavernosum. During sexual arousal in the male, NO is released from neurones and the endothelium and binds to and activates soluble guanylate cyclase (sGC) located in the smooth muscle cells and endothelium, leading to an elevation in intracellular cyclic guanosine 3′,5′-monophosphate (cGMP) levels. This rise in cGMP leads to a relaxation of the corpus cavernosum due to a reduction in the intracellular calcium concentration ([Ca²⁺]_(i)), via unknown mechanisms thought to involve protein kinase G activation (possibly due to activation of Ca²⁺ pumps and Ca²⁺-activated K⁺ channels).

The categories of female sexual dysfunction (FSD) are best defined by contrasting them to the phases of normal female sexual response: desire, arousal and orgasm (see S R Leiblum, (1998), Definition and Classification of Female Sexual Disorders, Int. J. Impotence Res., 10, S104–S106). Desire or libido is the drive for sexual expression. Its manifestations often include sexual thoughts either when in the company of an interested partner or when exposed to other erotic stimuli. Arousal includes the vascular response to sexual stimulation, an important component of which is genital engorgement and increased vaginal lubrication, elongation of the vagina and increased genital sensation/sensitivity and a subjective excitement response. Orgasm is the release of sexual tension that has culminated during arousal. Hence, FSD occurs when a woman has an absent, inadequate or unsatisfactory response in any one or more of these phases, usually desire, arousal or orgasm.

The American Psychiatric Association classifies female sexual dysfunction (FSD) into four classes: FSAD, hypoactive sexual desire disorder (HSDD), female orgasmic disorder (FOD), and sexual pain disorders (e.g. dyspareunia and vaginismus) [see the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)].

DSM-IV defines the four classes as follows:

HSDD—Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity. The judgment of deficiency or absence is made by the clinician, taking into account factors that affect functioning, such as age and the context of the persons life.

FSAD—Persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate lubrication-swelling response of sexual excitement.

FOD—Persistent or recurrent delay in, or absence of, orgasm following a normal sexual excitement phase. Women exhibit wide variability in the type or intensity of stimulation that triggers orgasm. The diagnosis of FOD should be based on the clinician's judgment that the woman's orgasmic capacity is less than would be reasonable for her age, sexual experience, and the adequacy of the sexual stimulation she receives.

Sexual Pain Disorders such as Dyspareunia and Vaginismus. Dysparenuia—Recurrent or persistent genital pain associated with sexual intercourse. Vaginismus—Recurrent or persistent involuntary spasm of the musculature of the outer third of the vagina that interferes with sexual intercourse.

HSDD is present if a woman has no or little desire to be sexual, and has no or few sexual thoughts or fantasies. This type of FSD can be caused by low testosterone levels, due either to natural menopause or to surgical menopause. Other causes in both pre-menopausal woman (i.e. woman who are pre-menopausal and who have not have hysterectomies) as well as post-menopausal women include illness, medications, fatigue, depression and/or anxiety. Factors having a potential (conscious or sub-conscious) psychological impact such as relationship difficulties or religious factors may be related to the presence of/development of HSDD in females. The Diagnostic and Statistical Manual (DSM) IV of the American Psychiatric Association defines Female Sexual Arousal Disorder (FSAD) as being: “ . . . a persistent or recurrent inability to attain or to maintain until completion of the sexual activity adequate lubrication-swelling response of sexual excitement. The disturbance must cause marked distress or interpersonal difficulty. . . . ”.

The arousal response consists of vasocongestion in the pelvis, vaginal lubrication and expansion and swelling of the external genitalia. The disturbance causes marked distress and/or interpersonal difficulty.

FSAD is a highly prevalent sexual disorder affecting pre-, peri- and post-menopausal (±hormone replacement therapy (HRT)) women. It is associated with concomitant disorders such as depression, cardiovascular diseases, diabetes and urogenital (UG) disorders. The primary consequences of FSAD are lack of engorgement/swelling, lack of lubrication and lack of pleasurable genital sensation. The secondary consequences of FSAD are reduced sexual desire, pain during intercourse and difficulty in achieving an orgasm. It has recently been hypothesized that there is a vascular basis for at least a proportion of patients with symptoms of FSAD (Goldstein et al., Int. J. Impot. Res., 10, S84–S90, 1998) with animal data supporting this view (Park et al., Int. J. Impot. Res., 9, 27–37, 1997).

Drug candidates for treating FSAD, which are under investigation for efficacy, are primarily erectile dysfunction therapies that promote circulation to male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. Sildenafil), and prostaglandin (PGE₁) that are injected or administered transurethrally in men and topically to the genitalia in women.

The compounds of the present invention are advantageous by providing a means for restoring a normal sexual arousal response—namely increased genital blood flow leading to vaginal, clitoral and labial engorgement. This will result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased genital sensitivity. Hence, the present invention provides a means to restore, or potentiate, the normal sexual arousal response.

By female genitalia herein we mean: “The genital organs consist of an internal and external group. The internal organs are situated within the pelvis and consist of ovaries, the uterine tubes, uterus and the vagina. The external organs are superficial to the urogenital diaphragm and below the pelvic arch. They comprise the mons pubis, the labia majora and minora pudendi, the clitoris, the vestibule, the bulb of the vestibule, and the greater vestibular glands” (Gray's Anatomy, C. D. Clemente, 13^(th) American Edition). R. J. Levin teaches us that because “ . . . male and female genitalia develop embryologically from the common tissue anlagen, [that] male and female genital structures are argued to be homologues of one another. Thus the clitoris is the penile homologue and the labia homologues of the scrotal sac. . . . ” (Levin, R. J. (1991), Exp. Clin. Endocrinol., 98, 61–69).

In summary, FSAD is characterized by inadequate genital response to sexual stimulation. The genitalia do not undergo the engorgement that characterizes normal sexual arousal. The vaginal walls are poorly lubricated, so that intercourse is painful. Orgasms may be impeded. Arousal disorder can be caused by reduced oestrogen at menopause or after childbirth and during lactation, as well as by illnesses, with vascular components such as diabetes and atherosclerosis. Other causes result from treatment with diuretics, antihistamines, antidepressants e.g. selective serotonin reuptake inhibitors (SSRIs) or antihypertensive agents.

FOD is the persistent or recurrent difficulty, delay in or absence of attaining orgasm following sufficient sexual stimulation and arousal, which causes personal distress.

Sexual pain disorders (includes dyspareunia and vaginismus) are characterized by pain resulting from penetration and sexual activity and may be caused by medications which reduce lubrication, endometriosis, pelvic inflammatory disease, inflammatory bowel disease or urinary tract problems.

According to a further aspect, the present invention additionally provides a method for the treatment and/or prevention of male sexual dysfunction (MSD), in particular male erectile dysfunction (MED) via treatment with a compound of the present invention as detailed herein before.

According to a yet further aspect, the present invention additionally provides a method for the treatment and/or prevention of male sexual dysfunction via treatment with a combination of a compound of the present invention as defined hereinbefore and one or more compounds which inhibit the activity of PDE, in particular compounds which inhibit the activity of cGMP PDE5, and/or one or more compounds which inhibit the activity of NEP.

Men who display an insufficient response or lack of response to treatment with Viagra™ may benefit either from therapy based on treatment with compounds of the present invention alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example sildenafil. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or in combination with a NEPi, and patients with severe MED may also respond. Mild, moderate and severe MED will be terms known to the man skilled in the art, but guidance can be found in: The Journal of Urology, vol 151, 54–61 (January 1994).

MED patient groups, which are described in more detail in Clinical Andrology vol 23, no. 4, p 773–782, and chapter 3 of the book by I. Eardley and K. Sethia “Erectile Dysfunction—Current Investigation and Management, published by Mosby-Wolfe, are as follows: psyhcogenic, endocrinologic, neurogenic, arteriogenic, drug-induced sexual dysfunction (lactogenic) and sexual dysfunction related to cavernosal factors, particularly venogenic causes.

Suitable cGMP PDE5 inhibitors for the use in combination with a compound of the present invention for the treatment of MED according to the present invention include: the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in EP-A-0463756; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international application WO 01/27112; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international application WO 01/27113; the indole-1,4-diones disclosed in WO95/19978 and the triazin-4-ones disclosed in published international application WO99/24433.

More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, also known as 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimid in-5-yl]-3-pyridylsulphonyl}-4-ethylpiperazine (see WO 01/27113, Example 8);

5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27112, Example 132);

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2′,1′:6, 1]pyrido[3,4-b]indole-1,4-dione (IC-351, tadalafil), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples 1, 3, 7 and 8; and

2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5, 1-f[]1,2,4]triazin-4-one (vardenafil) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5, 1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433); and pharmaceutically acceptable salts thereof.

According to a further aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and sildenafil.

The suitability of any particular cGMP PDE5 inhibitor for use in combination with a compound of the present invention can be readily determined by evaluation of its potency and selectivity using literature methods followed by evaluation of its toxicity, absorption, metabolism, pharmacokinetics, etc in accordance with standard pharmaceutical practice.

Preferred cGMP PDE5 inhibitors for use herein have an IC₅₀ at less than 100 nanomolar, more preferably, at less than 50 nanomolar, more preferably still at less than 10 nanomolar. Preferably the cGMP PDE5 inhibitors for use in the pharmaceutical combinations according to the present invention are selective for the PDE5 enzyme. Preferably they have a selectivity of PDE5 over PDE3 of greater than 100 more preferably greater than 300. More preferably the PDE5 has a selectivity over both PDE3 and PDE4 of greater than 100, more preferably greater than 300.

Selectivity ratios may readily be determined by the skilled person. IC₅₀ values for the PDE3 and PDE4 enzyme may be determined using established literature methodology, see S A Ballard et al, Journal of Urology, 1998, vol. 159, pages 2164–2171.

Preferred herein are NEP inhibitors wherein said NEP is EC 3.4.24.11 and more preferably wherein said NEP inhibitor is a selective inhibitor for EC 3.4.24.11, more preferably a selective NEP inhibitor is a selective inhibitor for EC 3.4.24.11, which has an IC₅₀ of less than 100 nM (e.g. ompatrilat, candoxatril, candoxatrilat, sampatrilat). Suitable NEP inhibitor compounds are described in EP-A-1097719.

Particularly preferred NEPi compounds for as auxiliary agents for use in the treatment of MED according to the present invention are those described in co-pending International Patent Application PCT/IB02/00807 filed on the 18th March 2002.

Especially preferred is (S)-2-[(1-{[3-(4-chlorophenyl)propyl]-carbamoyl}cyclo-pentyl)methyl]-4-methoxybutanoic acid or a pharmacuetically acceptable salt such as the sodium salt thereof as detailed at Example 22 in PCT/IB02/00807. Details for the synthesis of this compound and the sodium salt are provided in the Experimental Section hereinafter.

According to a further aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and (S)-2-[(1-{[3-(4-chlorophenyl )propyl]carbamoyl}cyclopentyl)methyl]-4-methoxybutanoic acid.

According to yet a further aspect of the present invention, there is provided use of a compound of the present invention for the treatment of female sexual dysfunction (FSD).

According to another aspect of the present invention, there is provided use of a compound of the present invention and one or more additional active agents for the treatment of female sexual dysfunction (FSD).

Preferably, the one or more additional active agents is/are selected from the group consisting of:

-   -   1) estrogen receptor modulators and/or estrogen agonists and/or         estrogen antagonists;     -   2) testosterone replacement agent and/or testosternone         (Tostrelle) and/or dihydrotestosterone and/or         dehydroepiandrosterone (DHEA) and/or a testosterone implant;     -   3) estrogen, estrogen and medroxyprogesterone or         medroxyprogesterone acetate (MPA) (as a combination), or         estrogen and methyl testosterone hormone replacement therapy         agent;     -   4) one or more dopaminergic agents;     -   5) one or more of an NPY (neuropeptide Y) inhibitor;     -   6) one or more of a melanocortin receptor agonist or modulator         or melanocortin enhancer;     -   7) one or more of an NEP (neutral endopeptidase) inhibitor;     -   8) one or more of a PDE (phosphodiesterase) inhibitor; and     -   9) one or more of a bombesin receptor antagonist or modulator.

Preferably, said FSD is female sexual arousal disorder (FSAD). Alternatively, said FSD is female orgasmic disorder (FOD). In a further alternative, said FSD is hypoactive sexual desire disorder (HSDD). In yet a further alternative, said FSD is a sexual pain disorder, preferably Dyspareunia or Vaginismus.

Examples of estrogen receptor modulators and/or estrogen agonists and/or estrogen antagonists, include raloxifene or lasofoxifene, (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol and pharmaceutically acceptable salts thereof (compound (a) below), the preparation of which is detailed in WO 96/21656.

An example of a testosterone replacement agent is dehydroandrostendione.

Examples of hormone replacement therapy agent include Premarin, Cenestin, Oestrofeminal, Equin, Estrace, Estrofem, Elleste Solo, Estring, Eastraderm TTS, Eastraderm Matrix, Dermestril, Premphase, Preempro, Prempak, Premique, Estratest, Estratest HS, and Tibolone.

Examples of dopaminergic agents include apomorphine or a selective D2, D3 or D2/D₃agonist such as, pramipexole and ropirinol (as claimed in WO-0023056),L-Dopa or carbidopa, PNU95666 (as disclosed in WO-0040226).

Examples of NPY (neuropeptide Y) inhibitors include NPY1 or NPY5 inhibitors, preferably NPY1 inhibitor. Preferably, said NPY inhibitors (including NPY Y1 and NPY Y5) having an IC50 of less than 100 nM, more preferably less than 50 nM. Suitable NPY, and in particular NPY1 inhibitor compounds, are described in EP-A-1097718.

Examples of a melanocortin receptor agonist or modulator or melanocortin enhancer include melanotan II, PT-14, PT-141 or compounds disclosed in WO-09964002, WO-00074679, WO-09955679, WO-00105401, WO-00058361, WO-00114879, WO-00113112 or WO-09954358.

Suitable NEP inhibitors are as described hereinabove.

According to a further aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and (S)-2-[(1-{[3-(4-chlorophenyl)propyl]carbamoyl}cyclopentyl)methyl]-4-methoxybutanoic acid.

Preferred PDE inhibitors include a PDE 2, 3, 4, 5, 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably sildenafil.

According to a further aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and sildenafil.

Preferred examples of one or more of bombesin receptor antagonists or modulators would be antagonists or modulators for BB₁, including those described in PCT/GB01/05018 (filed 14 Nov. 2001) and PCT/GB00/04380 (filed 17 Nov. 2000). Also preferred are bombesin BB₂, BB₃, or BB₄ receptor antagonists. Preferred bombesin receptor antagonists are also mentioned as “auxiliary agents” in PCT/IB01/02399 (filed 10 Dec. 2001).

It should be noted that a full list of possible “additional active agents” can be found in PCT/IB01/02399 (filed 10 Dec. 2001)—and are described as “auxiliary agents” therein.

In accordance with yet another aspect of the present invention, other 5-HT_(2c) receptor agonists may be used in addition to a compound of the present invention. Such 5-HT_(2c) receptor agonists include, but are not limited to, those disclosed in Chaki and Nakazato—Expert Opin. Ther. Patents (2001), 11(11):1677–1692 (see especially Section 3.9–5HT_(2c) on page 1687 and FIG. 7 on page 1686), or Isaac—Drugs of the Future (2001), 26(4):383–393 (see especially FIG. 2 on page 385). For the avoidance of doubt, the aforementioned publications are incorporated herein by reference in their entireties.

Preferably, said 5-HT_(2c) receptor agonists are selective 5-HT_(2c) receptor agonists.

Receptor binding data or binding selectivity data may not always correlate with or reflect functional data or functional selectivity data. For example, a compound may be a 5-HT_(2c) receptor agonist when binding assays are analysed, but functionally the compound may have the same potency at other 5-HT receptors. Thus, the term “selective” as used herein in relation to the present invention with respect to methods of treatment for sexual dysfunction means “functionally selective”.

Thus, according to another aspect, the present invention additionally provides the use of 5-HT_(2c) receptor agonists, preferably selective 5-HT_(2c) receptor agonists, for the treatment of FSD, preferably FSAD, FOD, HSDD or a sexual pain disorder (such as Dyspareunia or Vaginismus).

According to the methods of the invention, a compound of the present invention or a combination of a compound of the present invention and at least one additional pharmaceutical agent is administered to a subject in need of such treatment, preferably in the form of a pharmaceutical composition. In the combination aspect of the invention, the compound of the present invention and at least one other pharmaceutical agent (e.g., anti-obesity agent described above) may be administered either separately or in the pharmaceutical composition comprising both. It is generally preferred that such administration be oral. However, if the subject being treated is unable to swallow, or oral administration is otherwise impaired or undesirable, parenteral or transdermal administration may be appropriate.

According to the methods of the invention, when a combination of a compound of the present invention and at least one other pharmaceutical agent are administered together, such administration can be sequential in time or simultaneous with the simultaneous method being generally preferred. For sequential administration, a compound of the present invention and the additional pharmaceutical agent can be administered in any order. It is generally preferred that such administration be oral. It is especially preferred that such administration be oral and simultaneous. When a compound of the present invention and the additional pharmaceutical agent are administered sequentially, the administration of each can be by the same or by different methods.

According to the methods of the invention, a compound of the present invention or a combination of a compound of the present invention and at least one additional pharmaceutical agent (referred to herein as a “combination”) is preferably administered in the form of a pharmaceutical composition. Accordingly, a compound of the present invention or a combination can be administered to a patient separately or together in any conventional oral, rectal, transdermal, parenteral, (for example, intravenous, intramuscular, or subcutaneous) intracisternal, intravaginal, intraperitoneal, intravesical, local (for example, powder, ointment or drop), or buccal, or nasal, dosage form.

Compositions suitable for parenteral injection generally include pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Prevention of microorganism contamination of the compositions can be accomplished with various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of injectable pharmaceutical compositions can be brought about by the use of agents capable of delaying absorption, for example, aluminum monostearate and gelatin.

Solid dosage forms for oral administration include capsules, tablets, powders, and granules. In such solid dosage forms, a compound of the present invention or a combination is admixed with at least one inert customary pharmaceutical excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders (e.g., starches, lactose, sucrose, mannitol, silicic acid and the like); (b) binders (e.g., carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, acacia and the like); (c) humectants (e.g., glycerol and the like); (d) disintegrating agents (e.g., agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, sodium carbonate and the like); (e) solution retarders (e.g., paraffin and the like); (f) absorption accelerators (e.g., quaternary ammonium compounds and the like); (g) wetting agents (e.g., cetyl alcohol, glycerol monostearate and the like); (h) adsorbents (e.g., kaolin, bentonite and the like); and/or (i) lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and the like). In the case of capsules and tablets, the dosage forms may also comprise buffering agents.

Solid compositions of a similar type may also be used as fillers in soft or hard filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols, and the like.

Solid dosage forms such as tablets, dragees, capsules, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may also contain opacifying agents, and can also be of such composition that they release the compound of the present invention and/or the additional pharmaceutical agent in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. The drug can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the compound of the present invention or the combination, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame seed oil and the like), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, or mixtures of these substances, and the like.

Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the compound of the present invention or the combination, may further comprise suspending agents, e.g., ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, or mixtures of these substances, and the like.

Compositions for rectal or vaginal administration preferably comprise suppositories, which can be prepared by mixing a compound of the present invention or a combination with suitable non-irritating excipients or carriers, such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ordinary room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity thereby releasing the active component(s).

Dosage forms for topical administration of the compounds of the present invention and. combinations of the compounds of the present invention with anti-obesity agents may comprise ointments, powders, sprays and inhalants. The drugs are admixed under sterile condition with a pharmaceutically acceptable carrier, and any preservatives, buffers, or propellants that may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also intended to be included within the scope of the present invention.

The following paragraphs describe exemplary formulations, dosages, etc. useful for non-human animals. The administration of the compounds of the present invention and combinations of the compounds of the present invention with anti-obesity agents can be effected orally or non-orally (e.g., by injection).

An amount of a compound of the present invention or combination of a compound of the present invention with an anti-obesity agent is administered such that an effective dose is received. Generally, a daily dose that is administered orally to an animal is between about 0.01 and about 1,000 mg/kg of body weight, preferably between about 0.01 and about 300 mg/kg of body weight.

Conveniently, a compound of the present invention (or combination) can be carried in the drinking water so that a therapeutic dosage of the compound is ingested with the daily water supply. The compound can be directly metered into drinking water, preferably in the form of a liquid, water-soluble concentrate (such as an aqueous solution of a water-soluble salt).

Conveniently, a compound of the present invention (or combination) can also be added directly to the feed, as such, or in the form of an animal feed supplement, also referred to as a premix or concentrate. A premix or concentrate of the compound in a carrier is more commonly employed for the inclusion of the agent in the feed. Suitable carriers are liquid or solid, as desired, such as water, various meals such as alfalfa meal, soybean meal, cottonseed oil meal, linseed oil meal, corncob meal and corn meal, molasses, urea, bone meal, and mineral mixes such as are commonly employed in poultry feeds. A particularly effective carrier is the respective animal feed itself; that is, a small portion of such feed. The carrier facilitates uniform distribution of the compound in the finished feed with which the premix is blended. Preferably, the compound is thoroughly blended into the premix and, subsequently, the feed. In this respect, the compound may be dispersed or dissolved in a suitable oily vehicle such as soybean oil, corn oil, cottonseed oil, and the like, or in a volatile organic solvent and then blended with the carrier. It will be appreciated that the proportions of compound in the concentrate are capable of wide variation since the amount of the compound in the finished feed may be adjusted by blending the appropriate proportion of premix with the feed to obtain a desired level of compound.

High potency concentrates may be blended by the feed manufacturer with proteinaceous carrier such as soybean oil meal and other meals, as described above, to produce concentrated supplements, which are suitable for direct feeding to animals. In such instances, the animals are permitted to consume the usual diet. Alternatively, such concentrated supplements may be added directly to the feed to produce a nutritionally balanced, finished feed containing a therapeutically effective level of a compound of the present invention. The mixtures are thoroughly blended by standard procedures, such as in a twin shell blender, to ensure homogeneity.

If the supplement is used as a top dressing for the feed, it likewise helps to ensure uniformity of distribution of the compound across the top of the dressed feed.

Drinking water and feed effective for increasing lean meat deposition and for improving lean meat to fat ratio are generally prepared by mixing a compound of the present invention with a sufficient amount of animal feed to provide from about 10⁻ to about 500 ppm of the compound in the feed or water.

The preferred medicated swine, cattle, sheep and goat feed generally contain from about 1 to about 400 grams of a compound of the present invention (or combination) per ton of feed, the optimum amount for these animals usually being about 50 to about 300 grams per ton of feed.

The preferred poultry and domestic pet feeds usually contain about 1 to about 400 grams and preferably about 10 to about 400 grams of a compound of the present invention (or combination) per ton of feed.

For parenteral administration in animals, the compounds of the present invention (or combination) may be prepared in the form of a paste or a pellet and administered as an implant, usually under the skin of the head or ear of the animal in which increase in lean meat deposition and improvement in lean meat to fat ratio is sought.

In general, parenteral administration involves injection of a sufficient amount of a compound of the present invention (or combination) to provide the animal with about 0.01 to about 20 mg/kg/day of body weight of the drug. The preferred dosage for poultry, swine, cattle, sheep, goats and domestic pets is in the range of from about 0.05 to about 10 mg/kg/day of body weight of drug.

Paste formulations can be prepared by dispersing the drug in a pharmaceutically acceptable oil such as peanut oil, sesame oil, corn oil or the like.

Pellets containing an effective amount of a compound of the present invention, pharmaceutical composition, or combination can be prepared by admixing a compound of the present invention or combination with a diluent such as carbowax, carnuba wax, and the like, and a lubricant, such as magnesium or calcium stearate, can be added to improve the pelleting process.

It is, of course, recognized that more than one pellet may be administered to an animal to achieve the desired dose level which will provide the increase in lean meat deposition and improvement in lean meat to fat ratio desired. Moreover, implants may also be made periodically during the animal treatment period in order to maintain the proper drug level in the animal's body.

The present invention has several advantageous veterinary features. For the pet owner or veterinarian who wishes to increase leanness and/or trim unwanted fat from pet animals, the instant invention provides the means by which this may be accomplished. For poultry and swine breeders, utilization of the method of the present invention yields leaner animals that command higher sale prices from the meat industry.

Embodiments of the present invention are illustrated by the following Examples. It is to be understood, however, that the embodiments of the invention are not limited to the specific details of these Examples, as other variations thereof will be known, or apparent in light of the instant disclosure, to one of ordinary skill in the art.

EXAMPLES

Unless specified otherwise, starting materials are generally available from commercial sources such as Aldrich Chemicals Co. (Milwaukee, Wis.), Lancaster Synthesis, Inc. (Windham, N.H.), Acros Organics (Fairlawn, N.J.), Maybridge Chemical Company, Ltd. (Cornwall, England), Tyger Scientific (Princeton, N.J.), and AstraZeneca Pharmaceuticals (London, England).

General Experimental Procedures

NMR spectra were recorded on a Varian Unity™ 400 (available from Varian Inc., Palo Alto, Calif.) at room temperature at 400 MHz for proton. Chemical shifts are expressed in parts per million (δ) relative to residual solvent as an internal reference. The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; bs, broad singlet; 2s, two singlets. Atmospheric pressure chemical ionization mass spectra (APCI) were obtained on a Fisons™ Platform II Spectrometer (carrier gas: acetonitrile: available from Micromass Ltd, Manchester, UK). Chemical ionization mass spectra (Cl) were obtained on a Hewlett-Packard™ 5989 instrument (ammonia ionization, PBMS: available from Hewlett-Packard Company, Palo Alto, Calif.). Electrospray ionization mass spectra (ES) were obtained on a Waters™ ZMD instrument (carrier gas: acetonitrile: available from Waters Corp., Milford, Mass.). Where the intensity of chlorine or bromine-containing ions are described, the expected intensity ratio was observed (approximately 3:1 for ³⁵Cl/³⁷Cl-containing ions and 1:1 for ⁷⁹Br/⁸¹Br-containing ions) and the intensity of only the lower mass ion is given. In some cases only representative ¹H NMR peaks are given. MS peaks are reported for all examples. Optical rotations were determined on a PerkinElmer™ 241 polarimeter (available from PerkinElmer Inc., Wellesley, Mass.) using the sodium D line (λ=589 nm) at the indicated temperature and are reported as follows [α]_(D) ^(temp), concentration (c=g/100 mL), and solvent.

Column chromatography was performed with either Baker™ silica gel (40 μm; J. T. Baker, Phillipsburg, N.J.) or Silica Gel 50 (EM Sciences™, Gibbstown, N.J.) in glass columns or in Flash 40 Biotage™ columns (ISC, Inc., Shelton, Conn.) under low nitrogen pressure.

Example 1 Preparation of Intermediate 4-(2-Chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester (I-1a)

To a solution of 2,4-dichloropyrimidine (3.00 g, 20.1 mmol) in 100 mL of ethanol was added powdered sodium carbonate (2.1 g, 20.1 mmol) and piperazine-1-carboxylic acid tert-butyl ester (3.75 g, 20.1 mmol). The reaction was heated to reflux for 5 hours, then cooled to room temperature and concentrated in vacuo. The residue was taken up in 400 mL of ethyl acetate and extracted with water (100 mL) and brine (100 mL). The organic phase was then dried over sodium sulfate, filtered, and concentrated in vacuo to a clear oil. Flash column chromatography (silica gel, gradient elution from 10% ethyl acetate-hexanes to 50% ethyl acetate-hexanes) yielded 4.63 g of the title compound (I-1a).

¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, 1H), 6.39 (d, 1H), 3.65–3.50 (m, 8H), 1.46 (s, 9H). MS (ES⁺) Calc: 298, Found: 299.1 (M+1).

Preparation of Intermediate 4-[2-(3.5-Difluoro-benzyloxy)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester (I-1b)

3,5-Difluorobenzyl alcohol (227.5 μL, 2.01 mmol) was dissolved into 15 mL of anhydrous tetrahydrofuran and treated with sodium hydride (80.3 mg, 60% dispersion in mineral oil, 2.01 mmol). This was stirred under nitrogen for 15 minutes at ambient temperature, then the reaction was treated with 4-(2-chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester (I-1a) (500 mg, 1.67 mmol) in one portion. The resultant mixture was refluxed under nitrogen for 4 hours. After cooling to room temperature, the reaction was poured into water (50 mL) and extracted with ethyl acetate (2×50 mL). The combined organic extracts were washed with brine (20 mL), then dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silica gel, 1:1 ethyl acetate:hexanes) to afford 605.2 mg of the title product (I-1b).

¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, 1H); 6.96 (d, 2H); 6.72 (t, 1H); 6.20 (d, 1H); 5.33 (s, 2H); 3.63 (bs, 4H); 3.50 (m, 4H); 1.47 (s, 9H). MS (ES⁺) Calc: 406.4, Found: 407.3 (M+1).

Preparation of 2-(3,5-Difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine (1-A)

To a solution of 4-[2-(3,5-difluoro-benzyloxy)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester (I-1b) (605.2 mg, 1.49 mmol) in 5 mL of dichloromethane was added trifluoroacetic acid (1.72 mL, 22.33 mmol) and the mixture was stirred for 3 h at ambient temperature. The reaction was concentrated in vacuo, and the residue dissolved in 1 M HCl_((aq)) (70 mL). This was extracted with ethyl acetate (40 mL), separated, and the aqueous layer was adjusted to a pH of 12 using 5 M KOH_((aq)). This aqueous mixture was extracted with dichloromethane (2×100 mL) and the combined organic extracts were dried over sodium sulfate and concentrated to give 414.3 mg of a clear colorless oil that was determined to be title compound (1-A).

¹H NMR (400 MHz, CD₃OD) δ 7.94 (d, 1H); 7.02 (dd, 2H); 6.84 (dt, 1H); 6.37 (d, 1H); 5.34 (s, 2H); 3.62 (bs, 4H); 2.81 (m, 4H). MS (APCI⁺) Calc: 306.3, Found: 307.3 (M+1).

Preparation of 2-(3,5-Difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine, hydrochloride (1-B)

2-(3,5-Difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine (1-A) (27.5 mg, 0.09 mmol) was dissolved in 1 mL of dichloromethane and treated with 1M hydrogen chloride in ether (89.8 μL, 0.09 mmol) and shaken for one minute. The reaction was then concentrated under a stream of nitrogen to give 30.8 mg of a yellow solid as the title compound (1-B).

¹H NMR (400 MHz, CD₃OD) δ 8.09 (d, 1H); 7.05 (dd, 2H); 6.88 (dt, 1H); 6.54 (d, 1H); 5.39 (s, 2H); 3.93 (m, 4H); 3.28 (m, 4H). MS (APCI⁺) Calc: 306.3, Found: 307.1 (M+1).

Preparation of 2-(3,5-Difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine, fumarate (1-C)

2-(3,5-Difluoro-benzyloxy)-4-piperazin-1-yl-pyrimidine (1-A) (414.3 mg, 1.35 mmol) was dissolved in 10 mL of 10:1 methanol:isopropyl ether and treated with a solution of 0.5 M fumaric acid in methanol (2.70 mL, 1.35 mmol) and stirred for 1 h. The resulting slurry was diluted with 35 mL of isopropyl ether and stirred for 10 min. Filtration followed by air drying provided 549.4 mg of the title compound (1-C).

¹H NMR (400 MHz, CD₃OD) δ 8.06 (d, 1H); 7.03 (dd, 2H); 6.86 (dt, 1H); 6.67 (s, 2H); 6.49 (d, 1H); 5.37 (s, 2H); 3.87 (m, 4H); 3.19 (m, 4H). MS (APCI⁺) Calc: 306.3, Found: 307.1 (M+1).

Using the appropriate starting materials, the compounds listed in Table 1 were prepared in an analogous manner to the sequence of reactions described above for the preparation of compound (1-A) and the corresponding hydrochloride and fumarate salts (1-B) and (1-C), respectively.

TABLE 1 MS EX. Found No. Compound Name Calc. (M + 1) 1-D 4-Methyl-2-(3-phenoxy-benzyloxy)-6- 376.4 377.1 piperazin-1-yl-pyrimidine 1-E 2-[1-(3-Fluoro-phenyl)-ethoxy]-4-methyl-6- 316.4 317.2 piperazin-1-yl-pyrimidine 1-F 4-Methyl-6-piperazin-1-yl-2-(3- 368.4 369.1 trifluoromethoxy-benzyloxy)-pyrimidine 1-G 2-(4-Chloro-benzyloxy)-4-methyl-6-piperazin-1- 318.0 319.1 yl-pyrimidine 1-H 2-[1-(2-Chloro-phenyl)-ethoxy]-4-methyl-6- 332.0 333.1 piperazin-1-yl-pyrimidine 1-I 2-(3-Chloro-benzyloxy)-4-methyl-6-piperazin-1- 318.0 319.1 yl-pyrimidine 1-J 2-[1-(3-Chloro-phenyl)-ethoxy]-4-methyl-6- 332.0 333.1 piperazin-1-yl-pyrimidine 1-K 2-(3-Methoxy-benzyloxy)-4-piperazin-1-yl- 300.4 301.2 pyrimidine 1-L 2-[1-(3-Fluoro-phenyl)-ethoxy]-4-piperazin-1-yl- 302.3 303.2 pyrimidine 1-M 4-Piperazin-1-yl-2-(3-trifluoromethoxy- 354.3 355.1 benzyloxy)-pyrimidine 1-N 2-(3-Chloro-benzyloxy)-4-piperazin-1-yl- 304.0 305.1 pyrimidine 1-O 2-[1-(3-Chloro-phenyl)-ethoxy]-4-piperazin-1- 318.0 319.1 yl-pyrimidine 1-P 2-Benzyloxy-4-methyl-6-piperazin-1-yl- 320.2 321.1 pyrimidine, hydrochloride 1-Q 2-(4-Chloro-benzyloxy)-4-piperazin-1-yl- 304.0 305.1 pyrimidine 1-R 2-[1-(2-Chloro-phenyl)-ethoxy]-4-piperazin-1- 318.0 319.1 yl-pyrimidine 1-S 2-(3,4-Dichloro-benzyloxy)-4-piperazin-1-yl- 338.0 339.0 pyrimidine 1-T 2-(4-Fluoro-benzyloxy)-4-piperazin-1-yl- 288.1 289.1 pyrimidine 1-U 2-(3,4-Difluoro-benzyloxy)-4-piperazin-1-yl- 306.1 307.1 pyrimidine 1-V 2-(2-Chloro-benzyloxy)-4-piperazin-1-yl- 304.1 305.1 pyrimidine, hydrochloride 1-W 2-(2-Fluoro-benzyloxy)-4-piperazin-1-yl- 288.1 289.1 pyrimidine, hydrochloride 1-X 2-(3-Fluoro-benzyloxy)-4-piperazin-1-yl- 288.1 289.1 pyrimidine, hydrochloride 1-Y 2-(2,3-Difluoro-benzyloxy)-4-piperazin-1-yl- 306.1 307.1 pyrimidine, hydrochloride 1-Z 2-(2,5-Difluoro-benzyloxy)-4-piperazin-1-yl- 306.1 307.1 pyrimidine, hydrochloride 1-AA 2-(2,6-Difluoro-benzyloxy)-4-piperazin-1-yl- 306.1 307.1 pyrimidine, hydrochloride 1-BB 2-(2-Chloro-6-fluoro-benzyloxy)-4-piperazin-1- 322.1 323.1 yl-pyrimidine, hydrochloride 1-CC 2-(3-Chloro-benzyloxy)-4-piperazin-1-yl- 304.1 305.1 pyrimidine, hydrochloride 1-DD 2-(2-Chloro-pyridin-3-ylmethoxy)-4-piperazin- 305.1 306.0 1-yl-pyrimidine, hydrochloride 1-EE 2-(2,5-Dichloro-benzyloxy)-4-piperazin-1-yl- 338.1 338.9 pyrimidine, hydrochloride 1-FF 2-(2,6-Dichloro-benzyloxy)-4-piperazin-1-yl- 338.1 338.9 pyrimidine, hydrochloride 1-GG 2-(2,3-Dichloro-benzyloxy)-4-piperazin-1-yl- 338.1 339.0 pyrimidine, hydrochloride 1-HH 2-(3,5-Dichloro-benzyloxy)-4-piperazin-1-yl- 338.1 339.0 pyrimidine, hydrochloride 1-II 4-Piperazin-1-yl-2-(2-trifluoromethoxy- 354.1 355.1 benzyloxy)-pyrimidine, hydrochloride 1-JJ 4-Piperazin-1-yl-2-(2-trifluoromethyl- 338.1 339.1 benzyloxy)-pyrimidine, hydrochloride 1-KK 2-(3-Chloro-benzyloxy)-4-[(2S)-methyl- 318.1 319.1 piperazin-1-yl]-pyrimidine, hydrochloride 1-LL 2-(3-Chloro-benzyloxy)-4-[(2R)-methyl- 318.1 319.1 piperazin-1-yl]-pyrimidine, hydrochloride 1- 2-(3-Chloro-benzyloxy)-4-[(3R)-methyl- 318.1 319.1 MM piperazin-1-yl]pyrimidine 1-NN 2-(3-Chloro-benzyloxy)-4-[(3R,5S)-dimethyl- 332.1 333.1 piperazin-1-yl]-pyrimidine 1-OO 4-Piperazin-1-yl-2-(2,3,5-trifluoro-benzyloxy)- 324.1 325.1 pyrimidine 1-PP 2-(5-Fluoro-2-trifluoromethyl-benzyloxy)-4- 356.1 357.1 piperazin-1-yl-pyrimidine 1-QQ 2-(3,5-Bis-trifluoromethyl-benzyloxy)-4- 406.1 407.1 piperazin-1-yl-pyrimidine 1-RR 2-(2,5-Dichloro-benzyloxy)-4-[(2R)-methyl- 352.1 353.2 piperazin-1-yl]-pyrimidine 1-SS 2-(3,5-Dichloro-benzyloxy)-4-[(2R)-methyl- 352.1 353.2 piperazin-1-yl]-pyrimidine 1-TT 2-(2,5-Difluoro-benzyloxy)-4-[(2R)-methyl- 320.1 321.3 piperazin-1-yl]-pyrimidine 1-UU 2-(3,5-Difluoro-benzyloxy)-4-[(2R)-methyl- 320.1 321.3 piperazin-1-yl]-pyrimidine 1-VV 2-(2,5-Dichloro-benzyloxy)-4-[(2S)-methyl- 352.1 353.2 piperazin-1-yl]-pyrimidine 1- 2-(2,5-Difluoro-benzyloxy)-4-[(2S)-methyl- 320.1 321.2 WW piperazin-1-yl]-pyrimidine 1XX 2-(3,5-Difluoro-benzyloxy)-4-[(2S)-methyl- 320.1 321.3 piperazin-1-yl]-pyrimidine 1-YY 4-Piperazin-1-yl-2-(3,4,5-trifluoro-benzyloxy)- 324.1 325.3 pyrimidine 1-ZZ 2-(3-Fluoro-5-trifluoromethyl-benzyloxy)-4- 356.1 357.3 piperazin-1-yl-pyrimidine 1-AB 2-[1-(3,5-Difluoro-phenyl)-ethoxy]-4-piperazin- 320.1 321.3 1-yl-pyrimidine 1-AC 2-(3,5-Dichloro-benzyloxy)-4-[(2S)-methyl- 352.1 353.2 piperazin-1-yl]-pyrimidine 1-AD 2-(3,5-Dimethyl-benzyloxy)-4-piperazin-1-yl- 298.1 299.3 pyrimidine 1-AE 2-(2,5-Dimethyl-benzyloxy)-4-piperazin-1-yl- 298.1 299.3 pyrimidine 1-AF 2-[(1R)-Phenyl-ethoxy]-4-piperazin-1-yl- 284.4 285.3 pyrimidine 1-AG 2-[(1S)-Phenyl-ethoxy]-4-piperazin-1-yl- 284.4 285.3 pyrimidine 1-AH 2-(3-Chloro-benzyloxy)-4-[(3S)-methyl- 318.1 319.5 piperazin-1-yl]-pyrimidine 1-AI 2-(3-Fluoro-benzyloxy)-4-[(3S)-methyl- 302.3 303.6 piperazin-1-yl]-pyrimidine 1-AJ 2-Benzyloxy-4-piperazin-1-yl-pyrimidine, 306.3 307.3 hydrochloride 1-AK 2-Benzyloxy-5-methyl-4-piperazin-1-yl- 320.0 321.1 pyrimidine, hydrochloride 1-AL 2-(3-Methoxy-benzyloxy)-4-methyl-6-piperazin- 314.4 315.4 1-yl-pyrimidine

Example 2 Preparation of Intermediate 4-(4-chloro-pyrimidin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester (I-2a)

To a suspension of 2,4-dichloropyrimidine (1.00 g, 6.71 mmol) in 13.4 mL of toluene was added 4-methyl-piperazine-1-carboxylic acid tert-butyl ester (1.34 g, 6.71 mmol). The reaction was heated to reflux overnight, then cooled to room temperature and concentrated in vacuo. The residue was taken up in 20 mL of water and extracted with ethyl acetate (2×40 mL). The combined organic layers were washed with brine (25 mL), then dried over sodium sulfate, filtered, and concentrated in vacuo to an off-white solid. Flash column chromatography (silica gel, gradient elution from 5% ethyl acetate-hexanes to 20% ethyl acetate-hexanes) yielded 1.14 g of the title compound (I-2a).

¹H NMR (400 MHz, CDCl₃) δ 8.15 (d, 1H); 6.52 (d, 1H); 3.80 (m, 4H); 3.48 (m, 4H); 1.47 (s, 9H). MS (APCI⁺) Calc: 298, Found: 299.1 (M+1).

Preparation of Intermediate 4-{4-[1-(2-chloro-phenyl)-ethoxy]-1-pyrimidin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester (I-2b)

1-(2-Chloro-phenyl)-ethanol (31.4 mg, 0.20 mmol) was dissolved into 1.7 mL of anhydrous tetrahydrofuran and treated with sodium hydride (8.0 mg, 60% dispersion in mineral oil, 0.20 mmol). This was stirred under nitrogen for 1 hour at ambient temperature, then the reaction was treated with 4-(4-chloro-pyrimidin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester (I-2a) (50 mg, 0.17 mmol) in one portion. The resultant mixture was refluxed under nitrogen for 4 hours. After cooling to room temperature, the reaction was poured into water (20 mL) and extracted with ethyl acetate (2×25 mL). The combined organic extracts were washed with brine (20 mL), then dried over sodium sulfate, filtered, and concentrated. The residue was purified by preparative TLC (7:13 ethyl acetate:hexanes) to afford 64.3 mg of the title product (I-2b).

¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, 1H); 7.38–7.13 (m, 4H); 6.35 (q, 1H); 6.02 (d, 1H); 3.62 (m, 4H); 3.30 (m, 4H); 1.57 (d, 3H); 1.45 (s, 9H). MS (APCI⁺) Calc: 418, Found: 419.1 (M+1).

Preparation of 4-[1-(2-Chloro-phenyl)-ethoxy]-2-piperazin-1-yl-pyrimidine (2-A)

To a solution of 4-{4-[1-(2-chloro-phenyl)-ethoxy]-pyrimidin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester (I-2b) (64.3 mg, 0.15 mmol) in 2.0 mL of dichloromethane was added trifluoroacetic acid (177.4 μL, 2.30 mmol) and the mixture was stirred for 1.5 h at ambient temperature. The reaction was concentrated, and the residue dissolved in 1 M HCl_((aq)) (10 mL). This was extracted with ethyl acetate (10 mL), separated, and the aqueous layer was adjusted to a pH of 12 using 5 M KOH_((aq)). This aqueous mixture was extracted with ethyl acetate (2×15 mL) and the combined organic extracts were dried over sodium sulfate and concentrated to give 58.2 mg of the title product (2-A).

¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, 1H); 7.38 (dd, 1H); 7.28 (d, 1H); 7.18–7.11 (m, 2H); 6.36 (q, 1H); 6.00 (d, 1H); 3.68 (bs, 4H); 2.82 (bs, 4H); 1.56 (d, 3H). MS (APCI⁺) Calc: 318, Found: 319.1 (M+1).

Preparation of 4-[1-(2-Chloro-phenyl)-ethoxy]-2-piperazin-1-yl-pyrimidine, trifluoroacetate (2-B)

To a solution of 4-{4-[1-(2-chloro-phenyl)-ethoxy]-pyrimidin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester (I-2b) (64.3 mg, 0.15 mmol) in 2.0 mL of dichloromethane was added trifluoroacetic acid (177.4 μL, 2.30 mmol) and the mixture was stirred for 1.5 h at ambient temperature. The reaction was concentrated, and the residue solvent exchanged 6×4 mL of hexanes. The residue was found to be 62.1 mg of the title compound (2-B).

¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, 1H); 7.38 (dd, 1H); 7.28 (d, 1H); 7.18–7.11 (m, 2H); 6.36 (q, 1H); 6.00 (d, 1H); 3.68 (bs, 4H); 2.82 (bs, 4H); 1.56 (d, 3H). MS (APCI⁺) Calc: 318, Found: 319.1 (M+1).

Using the appropriate starting materials, the compounds listed in Table 2 were prepared in an analogous manner to the sequence of reactions described above for the preparation of compound (2-A) and the corresponding trifluoroacetate salt (2-B). The hydrochloride salt was formed in a manner analogous to the procedure described for the formation of (1-B) in Example 1.

TABLE 2 MS Ex. Found No. Compound Name Calc. (M + 1) 2-C 4-[1-(3-Chloro-phenyl)-ethoxy]-2-piperazin- 318.0 319.2 1-yl-pyrimidine 2-D 4-[1-(4-Chloro-phenyl)-ethoxy]-2-piperazin- 318.0 319.2 1-yl-pyrimidine 2-E 4-(4-Fluoro-benzyloxy)-2-piperazin-1-yl- 288.3 289.2 pyrimidine 2-F 4-(3,4-Dichloro-benzyloxy)-2-piperazin-1-yl- 338.0 339.0 pyrimidine 2-G 4-(3,4-Difluoro-benzyloxy)-2-piperazin-1-yl- 306.3 307.1 pyrimidine 2-H 4-(3,4-Dimethyl-benzyloxy)-2-piperazin-1- 298.2 299.2 yl-pyrimidine, hydrochloride 2-I 4-(2,3-Difluoro-benzyloxy)-2-piperazin-1-yl- 306.1 307.1 pyrimidine, trifluoroacetate 2-J 4-[1-(3-Chloro-phenyl)-ethoxy]-6-methyl-2- 332.1 333.3 piperazin-1-yl-pyrimidine, trifluoroacetate 2-K 4-(2-Ethoxy-benzyloxy)-6-methyl-2- 328.4 329.3 piperazin-1-yl-pyrimidine, trifluoroacetate 2-L 4-Benzyloxy-2-piperazin-1-yl-pyrimidine, 343.3 344.3 hydrochloride

Example 3 Preparation of Intermediate 4-[2-(3-Chloro-benzylamino)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester (I-3a)

A mixture of 4-(2-chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester (100 mg, 0.33 mmol), 3-chlorobenzylamine (0.65 mL, 5.3 mmol) and potassium carbonate (71 mg, 0.67 mmol) in ethanol (5 mL) was heated at reflux for 7 days. The reaction mixture was cooled to room temperature, poured into H₂O (15 mL) and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with H₂O (3×15 mL), brine, dried (Na₂SO₄) and concentrated in vacuo. The residue was purified by preparative TLC (10% MeOH in CH₂Cl₂) to give a yellow solid. The yellow solid was triturated with MeOH (1 mL) and the solid was collected by filtration to give intermediate (I-3a) as a white solid (48.5 mg).

¹H NMR (400 MHz, CD₃OD) δ 7.74 (bs, 1H); 7.35–7.17 (m, 4H); 6.01 (bs, 1H); 4.45 (s, 2H); 3.54 (bs, 4H); 3.37 (bs, 4H); 1.44 (s, 9H). MS (ES⁺) Calc: 403.2, Found: 404.1 (M+1).

Preparation of (3-Chloro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine, hydrochloride (3-A)

To a solution of 4-[2-(3-chloro-benzylamino)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester (I-3a) (48.5 mg, 0.12 mmol) in CH₂Cl₂ (1 mL) was added trifluoroacetic acid (139 μL, 1.8 mmol). After stirring at room temperature for 3 h, the mixture was poured into 1N NaOH (10 mL) and extracted with CH₂Cl₂ (1×35 mL). The organic layer was washed with brine, dried and concentrated to afford the title compound as a free amine. The free amine in CH₂Cl₂ (1 mL) was added to 1M HCl in ether (0.10 mL, 0.10 mmol). After stirring for 10 min at room temperature, the solution was concentrated in vacuo to yield the hydrochloride salt (3-A) (32.4 mg) as a yellow solid.

¹H NMR (400 MHz, CD₃OD) δ 7.82 (d, 1H); 7.38 (s, 1H); 7.35–7.26 (m, 3H); 6.51 (d, 1H); 4.60 (s, 2H); 4.04 (bs, 4H); 3.29 (bs, 4H). MS (APCI⁺) Calc: 303.2, Found: 304.1 (M+1).

Preparation of (3-Chloro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine, fumarate (3-B)

To a solution of intermediate (I-3a) (274.2 mg, 0.90 mmol) in 10 mL of 10:1 methanol:isopropyl ether was added a solution of 0.5 M fumaric acid in methanol (1.80 mL, 0.90 mmol) and stirred for 1 h. The resulting slurry was diluted with 35 mL of isopropyl ether and stirred for 10 min. Filtration followed by air drying provided 356.8 mg of the title compound (3-B).

¹H NMR (400 MHz, CD₃OD) δ 7.81 (d, 1H); 7.32–7.18 (m, 4H); 6.67 (s, 2H); 6.16 (d, 1H); 4.50 (s, 2H); 3.80 (bs, 4H); 3.11 (bs, 4H). MS (APCI⁺) Calc: 303.2, Found: 304.3 (M+1).

Using the appropriate starting materials, the following compounds were prepared in an analogous manner to the sequence of reactions described for compound (3-A) above.

(3-Fluoro-benzyl)-(4-piperazin-1-yl-pyrimidin-2-yl)-amine, hydrochloride (3-C)

¹H NMR (400 MHz, CD₃OD) δ 7.82 (d, 1H); 7.30–7.26 (m, 1H); 7.12 (d, 1H); 7.05–7.02 (dd, 1H); 6.92–6.91 (td, 1H); 6.16 (d, 1H); 4.52 (s, 2H); 3.81–3.78 (m, 4H); 3.12–3.11 (m, 4H). MS (APCI+) Calc: 287.2, Found: 288.1 (M+1).

Benzyl-(4-piperazin-1-yl-pyrimidin-2-yl)-amine, hydrochloride (3-D)

MS (APCI⁺) Calc: 305.3, Found: 306.2 (M+1).

Example 4 Preparation of Intermediate 4-[4-(3-Chloro-benzylamino)-pyrimidin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester (I-4a)

A mixture of 4-(4-chloro-pyrimidin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester I-2a (100 mg, 0.33 mmol), 3-chlorobenzylamine (0.65 mL, 5.3 mmol) and potassium carbonate (71 mg, 0.67 mmol) in ethanol (5 mL) was heated at reflux for 24 h. The reaction mixture was cooled to room temperature, poured into H₂O (15 mL) and extracted with EtOAc (2×18 mL). The combined organic extracts were washed with H₂O (2×10 mL), brine, dried (Na₂SO₄) and concentrated in vacuo. The residue was purified by chromatography using 40% EtOAc in hexane as an eluting solvent to afford the title compound I-4a (93 mg) as a colorless oil.

¹H NMR (400 MHz, CD₃OD) δ 7.69 (d, 1H); 7.32 (s, 1H); 7.28–7.19 (m, 3H); 5.88 (d, 1H); 4.49 (s, 2H); 3.64–3.61 (m, 4H); 3.37–3.29 (m, 4H); 1.45 (s, 9H). MS (ES⁺) Calc: 403.2, Found: 404.0 (M+1).

Preparation of (3-Chloro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine, hydrochloride (4-A)

The title compound (4-A) was prepared from 4-[4-(3-chloro-benzylamino)-pyrimidin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester (I-4a) and TFA according to a procedure analogous to that described in Example 3.

¹H NMR (400 MHz, CD₃OD) δ 7.74 (d, 1H); 7.35–7.25 (m, 4H); 6.15 (d, 1H); 4.60 (s, 2H); 3.97–3.94 (m, 4H); 3.27–3.23 (m, 4H). MS (APCI⁺) Calc: 303.2, Found: 304.1 (M+1).

Using the appropriate starting materials, compound (4-B) was prepared in an analogous manner to the sequence of reactions described for compound (4-A) above and the corresponding fumarate salt (4-C) was prepared using a procedure analogous to the process for preparing the fumarate salt described in Example 3 (compound (3-B)).

(3-Fluoro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine, hydrochloride (4-B)

¹H NMR (400 MHz, CD₃OD) δ 7.76 (d, 1H); 7.32–7.28 (m, 1H); 7.11 (d, 1H), 7.05–7.01 (dd, 1H), 6.93 (td, 1H); 5.94 (d, 1H); 4.53 (s, 2H); 3.90–3.87 (m, 4H); 3.13–3.11 (m, 4H). MS (APCI⁺) Calc: 287.2, Found: 288.1 (M+1).

(3-Fluoro-benzyl)-(2-piperazin-1-yl-pyrimidin-4-yl)-amine, fumarate (4-C)

¹H NMR (400 MHz, CD₃OD) δ 7.75 (d, 1H); 7.30 (dd, 1H); 7.11 (d, 1H), 7.02 (d, 1H), 6.93 (td, 1H); 6.69 (s, 3H) 5.94 (d, 1H); 4.53 (s, 2H); 3.87 (m, 4H); 3.13–3.11 (m, 4H). MS (APCI⁺) Calc: 287.2, Found: 288.1 (M+1).

Benzyl-(2-piperazin-1-yl-pyrimidin-4-yl)-amine, hydrochloride (4-D)

MS (APCI⁺) Calc: 305.3, Found: 306.2 (M+1).

Example 5 Preparation of Intermediate (6-Chloro-pyridin-2-yl)-methanol (I-5a)

A dry flask was charged with 25 mL of anhydrous tetrahydrofuran and 6-chloropyridine-2-carboxylic acid (2.00 g, 12.69 mmol) and then cooled to 10° C. This was treated dropwise with tetrahydrofuran-borane (1.0 M solution in THF, 38.1 mL) over 10 minutes under nitrogen. This was stirred with cooling for 15 minutes, then at ambient temperature for 4 h. The reaction was then cooled to 0° C., and 10 mL of water were added slowly. The resultant mixture was poured into 50 mL of 1 M aqueous sodium hydroxide and extracted 2×75 mL of ethyl acetate. The organic extracts were combined and washed with brine, then dried over sodium sulfate and filtered. Concentration in vacuo yielded 589.1 mg of a white solid as the title compound (I-5a).

¹H NMR (400 MHz, CDCL₃) δ 7.67 (t, 1H); 7.25 (m, 2H); 4.74 (s, 2H). MS (ES⁺) Calc: 143, Found: 144.3 (M+1).

Preparation of Intermediate 4-[2-(6-Chloro-pyridin-2-ylmethoxy)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester (I-5b)

The title compound (I-5b) was prepared from (6-chloro-pyridin-2-yl)-methanol (I-5a) and 4-(2-chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester (I-1 a) according to a procedure analogous to that described in Example 1.

¹H NMR (400 MHz, CDCL₃) δ 8.03 (d, 1H); 7.63 (t, 1H); 7.43 (d, 1H); 7.21 (d, 1H); 6.16 (d, 1H); 5.42 (s, 2H); 3.59 (m, 4H); 3.45 (m, 4H); 1.46 (s, 9H). MS (ES⁺) Calc: 405, Found: 406.1 (M+1).

Preparation of 2-(6-Chloro-pyrdin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine, hydrochloride (5-A)

The title compound (5-A) was prepared from 4-[2-(6-chloro-pyridin-2-ylmethoxy)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester (I-5b) and TFA according to a procedure analogous to that described in Example 3.

¹H NMR (400 MHz, CD₃OD) δ 8.08 (d, 1H); 7.80 (t, 1H); 7.46 (d, 1H); 7.36 (d, 1H); 6.53 (d, 1H); 5.41 (s, 2H); 3.91 (m, 4H); 3.27 (m, 4H). MS (ES⁺) Calc: 305, Found: 306.0 (M+1).

Using the appropriate starting materials, the compounds listed in Table 4 were prepared in an analogous manner to the sequence of reactions described above for the preparation of compound (5-A).

TABLE 4 MS Ex. Found No. Compound Name Calc. (M + 1) 5-B 4-Piperazin-1-yl-2-(pyridin-2-ylmethoxy)- 271.1 272.0 pyrimidine, hydrochloride 5-C 2-(6-Methyl-pyridin-2-ylmethoxy)-4- 285.1 286.0 piperazin-1-yl-pyrimidine, hydrochloride

Example 6

Example 6 illustrates the synthesis of NEPi Compound-(S)-2-[(1-{[3-(4-chlorophenyl)propyl]carbamoyl}cyclopentyl)methyl]-4-methoxy-butanoic acid referred to herein below for use in combination with the compounds of the present invention for treating female sexual dysfunction.

Preparation of Intermediate 1-[2-(tert-Butoxycarbonyl)-4-methoxybutyl]-cyclopentanecarboxylic acid (I-6a)

A solution of tert-butyl 3-(1-carboxycyclopentyl)propanoate (12 g, 49.5mmol) (see EP274234B1, Example 35) in dry tetrahydrofuran (100 ml) was added to a stirred solution of lithium diisopropylamide (130 ml) in a mixture of hexane (52 ml) and tetrahydrofuran (200 ml) at −78° C. under nitrogen. After 1 hour a solution of 2-bromoethyl methyl ether in tetrahydrofuran (100 ml) was added maintaining the temperature at −78° C. The reaction mixture was allowed to warm up to room temperature overnight. The mixture was quenched with water (100 ml) and acidified to pH 1 with 2M hydrochloric acid, and extracted with ethyl acetate (2×150 ml). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to give the crude acid which was chromatographed on silica. Elution with increasing proportions of methanol in dichloromethane (neat dichloromethane to 1:50) gave an oil (7.7 g, 25.6 mmol, 52%); Rf 0.3 methanol, dichloromethane 1:20;

¹H NMR (CDCl₃400 MHz) δ: 1.4 (s, 9H), 1.4–1.7 (m, 7H), 1.75–1.95 (m, 2H), 2.0–2.15 (m, 3H), 2.3–2.4 (m, 1H), 3.3 (s, 3H), 3.3–3.4 (m, 2H); LRMS: m/z 299 (M−H⁺).

Preparation of Intermediate 1-[(2S)-2-(tert-Butoxycarbonyl)-4-methoxybutyl]-cyclopentanecarboxylic acid (I-6b)

Intermediate I-6a and (+)-pseudoephedrine were recrystallised nine times from hexane to give a white crystaline solid. The salt was dissolved in ethyl acetate washed with 0.5M hydrochloric acid dried over magnesium sulphate and concentrated in vacuo the (S)-acid was obtained in 31% yield as a pale yellow oil in >90% ee (enantiomeric excess) by NMR analysis of the δ 3.3 peak of the (+)-pseudoephedrine salt;

¹H NMR (CDCl₃400 MHz) δ: 1.4 (s, 9H), 1.4–1.7 (m, 7H), 1.75–1.9 (m, 2H), 2.0–2.15 (m, 3H), 2.35–2.45 (m, 1H), 3.3 (s, 3H), 3.3–3.4 (m, 2H); [α]_(D)-5.2 (EtOH, c 1.2).

Preparation of Intermediate tert-butyl (2S)-2-{[1-({[3-(4-chlorophenylpropyl]amino}carbonyl) cyclopentyl]methyl}-4-methoxybutanoate (I-6c)

To a solution of 1,1′-carbonyl diimidazole (73.9 g, 0.45 mol) in azeotropically dried isopropyl acetate (339 ml) was added the isopropyl acetate solution of the Intermediate I-6b with stirring at 60° C. under an atmosphere of N₂ over a period of 1.5 hours. The transfer lines were then washed with dry isopropyl acetate (50 ml). The resultant solution was then stirred at 60° C. for a further 4.5 hours and then the reaction mixture was allowed to cool to room temperature and stirred for 15 hours. To the resultant solution was then added triethylamine (46.1 g, 0.46 mol), followed by 3-(4-chlorophenyl)-propylamine hydrochloride (J. Med. Chem., 1996, 39, 4942–51)(94.3 g, 0.46 mol). The resultant mixture was then heated to 60° C. for 7 hours before cooling to room temperature. Deionised water (100 ml) was then added to the reaction mixture with stirring, followed by aqueous hydrochloric acid (190 ml of a 5 M solution) until the pH of the aqueous layer was between pH 2 and 3. The aqueous layer was then separated, and the organic layer was washed with aqueous potassium carbonate (50 ml of a 0.5 M solution). The aqueous phase was separated and organic phase was washed with saturated brine solution (100 ml). The aqueous layer was then separated and the organic phase was concentrated by distillation under vacuum to give the title compound as a yellow oil (200.3 g, 443 mmol, 98% yield);

¹H NMR (CDCl₃300 MHz) δ: 1.45 (s, 9H), 1.45–1.56 (m, 1H), 1.56–1.74 (m, 6H), 1.74–2.11 (m, 7H), 2.32–2.43 (m, 1H), 2.64 (t, 2H), 3.22–3.30 (m, 2H), 3.27 (s, 3H), 3.30–3.38 (m, 2H), 5.75–5.85 (m, br, 1H), 7.13 (d, 2H), 7.26 (d, 2H); LRMS (ES positive): m/z 452 [M+H]⁺(³⁵Cl).

Preparation of (2S)-2-{[1-({[3-(4-Chlorophenyl)propyl]amino}carbonyl)-cyclopentyl]methyl}-4-methoxybutanoic acid and its sodium salt (6-A)

To a solution of Intermediate I6c (9.6 g, 21.2 mmol) in dichloromethane (52 ml) was added trifluoroacetic acid (16.3 ml, 212 mmol) and the resultant solution was stirred at room temperature for 3.75 hours under an atmosphere of N₂. To the reaction was then added aqueous sodium carbonate solution (95 ml of a 10% w/v solution) with stirring until the pH of the aqueous layer was between pH 2 and 3. The layers were then separated and the organic layer was extracted with aqueous sodium carbonate solution (2×20 ml of a 10% w/v solution). The aqueous layers were combined and saturated brine (80 ml) was then added, followed by 2-butanone (40 ml). The layers were separated and the aqueous layer was extracted again with 2-butanone (2×50 ml). The combined organic layers were then dried by azeotropic distillation at atmospheric pressure to a volume of 70 ml whereupon crystallisation occurred and the mixture was diluted with 2-butanone (70 ml). The product was then collected by filtration and dried at 50° C. for 65 hours under vacuum to give the crude sodium salt of the title compound as a white solid (5.76 g) that was then purified by recrystallisation as follows. To the crude product was added ethyl acetate (87 ml) and ethanol (13 ml) and the remaining insoluble material was removed by filtration. The ethanol was then removed by azeotropic distillation at atmospheric pressure (to remove 110 ml of solvent) and replaced with ethyl acetate (145 ml) whereupon crystallisation occurred. The resultant crystallised product was then collected by filtration under vacuum to give the pure sodium salt of the title product as a white crystalline solid (4.51 g, 10.8 mmol, 51%); m.p. (ethyl acetate) 214–216° C.;

¹H NMR (DMSO-d₆300 MHz) δ: 1.26–1.58 (m, 8H), 1.62–1.74 (m, 3 H), 1.74–1.86 (m, 1H), 1.91–2.07 (m, 3H), 2.57 (t, 2H), 3.03 (q, 2H), 3.10 (s, 3H), 3.13–3.27 (m, 2H), 7.22 (d, 2H), 7.29 (d, 2H), 9.16 (t, br, 1H); LRMS (ES negative); 789[2M−H]⁻ (³⁵Cl), 394[M−H]⁻ (³⁵Cl).

For analytical purposes the title product (i.e. the free acid) was obtained by dissolving this sodium salt in water, acidified with 5 M hydrochloric acid and extracted with dichloromethane. Removal of the solvent by blowing a stream of nitrogen over the sample gave the title product;

¹H NMR (DMSO-d₆300 MHz) δ: 1.22–1.80 (m, 11H), 1.81–1.96 (m, 2H), 1.96–2.08 (m, 1H), 2.93–2.27 (m, 1H), 2.53 (t, 2H), 3.03 (q, 2H), 3.11 (s, 3H), 3.16–3.25 (m, 2H), 7.20 (d, 2H), 7.30 (d, 2H), 7.51 (t, 1H); LRMS (ES negative); 789[2M−H]⁻ (³⁵Cl), 394[M−H]⁻ (³⁵Cl); HPLC (column: ChiralPak AS (25×0.46 cm); mobile phase: hexane/IPA/acetic acid (95/5/0.5 v/v/v); flow rate: 1.0 ml/min; temperature: ambient; injection volume: 20 μl; detection: UV@ 220 nm; Sample concentration: 1.0 mg/ml prepared in mobile phase) Retention Time: minor enantiomer 11.4 min (5.7%), major enantiomer 14.3 min (94.3%).

Preparation of Mono-Hydrate of the Sodium Salt of 6-A

To the sodium salt of 6-A (200 mg) was added to 1 ml of a 3.9% water in isopropanol solution. The resulting slurry was stirred for 12 days whereupon it was isolated by filtration. The product gave the following PXRD pattern listed in Table 5 below.

TABLE 5 Angle Intensity % 2-Theta° % 3.552 30.8 7.154 8 9.526 3.1 10.359 15.7 10.608 14.3 11.03 5 12.369 3.7 12.939 13.2 13.233 12.3 13.835 14.2 14.345 37.9 14.887 16 15.16 16.8 16.372 24.9 16.813 6.9 17.203 22.1 17.408 32.7 17.708 13.5 17.93 29 18.313 12 18.545 23.9 18.811 14 19.7 34.2 19.978 100 20.273 90.6 20.627 51.9 20.829 29.4 20.926 28.4 21.443 52.7 21.611 41.6 21.881 21.2 22.174 24.3 22.472 47.1 22.881 35 23.141 23.2 23.478 15.1 24.088 13.9 24.313 12.6 24.588 22.7 25.013 25.8 25.514 29.9 25.987 25.5 27.107 18.2 27.395 30.6 27.869 19.2 28.716 21 28.788 19 28.989 27.2 30.232 13.4 30.672 15 30.952 17.5 31.437 15.7 31.788 13.9 32.114 24.6 32.998 13.3 33.375 18.8 33.815 14 34.266 14.4 35.705 15.7 35.989 14.1 36.514 16.7 38.151 14.6 38.925 17 39.091 19 39.961 13 Differential scanning calorimetry (DSC) was performed using a Perkin Elmer DSC-7 instrument fitted with an automatic sample changer. Approximately 3 mg of the sample was accurately weighed into a 50 microliter aluminium pan and crimp sealed with a perforated lid. The samples were heated at 20° C./minute over the range 40° C. to 300° C. with a nitrogen gas purge. Dehydration events occurred at between 50 and 150° C. and a main melt between 212 and 225° C. The skilled person will appreciate that the melting point may vary outside this range as a result of sample impurity. Anhydrous Salt:

The sodium salt of compound 6-A gave the following PXRD pattern listed in Table 6 below.

TABLE 6 Angle Intensity % 2-Theta° % 5.463 12.2 6.654 100 7.546 66 9.336 31.3 10.953 9.7 11.571 55.9 12.56 10.9 13.287 22.9 15.125 33.6 15.667 60.3 16.403 17.2 17.024 62.2 17.714 95.6 18.083 31.7 18.64 28.8 18.902 82.4 19.696 40.1 20.406 33.9 20.502 31.8 20.683 45.4 20.942 31.5 21.559 92.6 21.898 66.2 22.274 36.6 22.735 30 23.36 56.5 24.126 31.9 24.388 45.2 24.72 25.8 25.298 26.7 25.579 20.4 26.718 17.6 27.151 24.2 27.46 22.7 27.737 20.2 28.56 27.1 28.926 23.8 29.802 23.5 30.454 30.7 30.885 29.2 31.48 21 32.66 16.8 34.027 23.1 34.494 17.6 36.011 19 36.997 17.4 38.704 21.2 39.961 18.7

Biological Assays

The utility of the compounds of the present invention in the practice of the instant invention can be evidenced by activity in at least one of the protocols described hereinbelow.

5HT_(2c) Binding Procedure

Affinity of compounds at the serotonin 5HT_(2c) binding site is determined by competition binding in Swiss 3T3 mouse cells (available from the American Type Culture Collection (ATCC), Manassas, Va.) transfected with the human 5HT_(2c) receptor against 3H-5HT. The method is adapted from Roth et al., J. of Pharm. And Exp. Therap., 260(3), 1362–1365 (1992). Cells are grown in DMEM high glucose medium, harvested, homogenized, centrifuged, and resuspended in 50 mM Tris-HCL. They are incubated at 37° C. for 15 minutes, centrifuged, and then resuspended into assay buffer (50 mM Tris-HCl, 4 mM CaCl₂, 0.1% ascorbic acid, and 100 μM pargyline at pH 7.7) at 100 volumes per gram. Assay tubes contain 25 μL of 10 nM ³H-5HT (1 nM final conc.), and 25 μl of vehicle (assay buffer), blank (10 μM mianserin), or test compound (10X final volume). 200 μl of tissue homogenate is added to each tube, vortexed, and incubated for 30 minutes at 37° C. Samples are then rapidly filtered under vacuum with a Skatron™ cell harvester (available from Molecular Devices Corporation, Sunnyvale, Calif.) using GF/B filters presoaked in 0.5% polyethyleneimine (PEI), and washed with 2×5 mL cold 50 mM Tris-HCl. Filter mats are removed and counted in a Wallac Betaplate counter (available from PerkinElmer Life Sciences, Gaithersburg, Md.). Percent inhibition of specific binding by test compounds is used to calculate the Ki, or extrapolate concentration of test compound necessary to inhibit one-half of the total specific binding for each compound.

The following compounds from the Examples above demonstrated a Ki value for 5HT_(2c) binding in the range of 0.2 nM to 238 nM:

Example Nos. 1-B, 1-D, 1-E, 1-F, 1-G, 1-H, 1-I, 1-J, 1-K, 1-L, 1-M, 1-O, 1-P, 1-Q, 1-R, 1-S, 1-T, 1-U, 1-V, 1-W, 1-X, 1-Y, 1-Z, 1-AA, 1-BB 1-DD, 1-EE, 1-FF, 1-GG, 1-HH, 1-II, 1-JJ, 1-KK, 1-LL, 1-MM, 1-CC, 1-OO, 1-PP, 1-QQ, 1-RR, 1-SS, 1-TT, 1-UU, 1-VV, 1-WW, 1-XX, 1-YY, 1-ZZ, 1-AB, 1-AC, 1-AD, 1-AE, 1-AJ, 1-AK, 1-AL, 2-A, 2-C, 2-D, 2-E, 2-F, 2-G, 2-H, 2-I, 2-L, 3-A, 3-C, 3-D, 4-A, 4-B, 4-D and 5-A. Example Nos. 1-NN, 5-B and 5-C demonstrated Ki values greater than 500 nM and the remaining compounds were not determined.

5HT_(2A) Binding Procedure

Affinity of compounds at the serotonin 5HT_(2A) binding site is determined by competition binding in NIH 3T3 mouse cells transfected with the rat 5HT_(2A) receptor using 1251-DOI. The method was adapted from Leonhardt et al., Molecular Pharmacology, 42, 328–335 (1992). Frozen cell paste is homgenized in 50 mM tris-HCl buffer pH 7.4 containing 2 mM MgCl₂ using a Polytron and centrifuged at 45000×g for ten minutes. The resulting pellet is resuspended in fresh ice-cold 50 mM tris-HCl buffer pH 7.4 containing 2 mM MgCl₂ using a Polytron™ and centrifuged again at 45000×g for ten minutes. The final pellet is resuspended in 50 mM tris-HCl buffer pH 7.4 containing 2 mM MgCl₂ at a concentration of 5 mg/mL. Wells in a 96 well plate contain 25 μL of 0.7 nM 1251-DOI (70 pM final conc.), and 25 μL of vehicle (assay buffer), blank (10 μM cinanserin), or test compound (10× final volume). 200 μl of tissue homogenate is added to each well and incubated for 15 minutes at 37° C. on a shaker. Samples are then rapidly filtered under vacuum with a cell harvester (Skatron™) using GF/B filters presoaked in 0.5% polyethyleneimine (PEI), and washed with 2×5 mL cold 50 mM tris-HCl. Filter mats are removed, dried and counted in a Wallac Betaplate counter. Concentration-response curves of the % inhibition of specific binding and log concentration by test compounds was used to determine the IC₅₀ for each compound and the Ki value calculated based on the Cheng-Prusof equation (Ki=IC50/(1+(L/Kd)), where L is the concentration of the radioligand used in the binding assay and the Kd is based on previous saturation studies with the radioligand.

The following compounds from the Examples above demonstrated a Ki value for 5HT_(2a) binding in the range of 0.5 nM to 625 nM:

Example Nos. 1-B, 1-D, 1-E, 1-F, 1-G, 1-H, 1-I, 1-J, 1-K, 1-L, 1-M, 1-O, 1-P, 1-Q, 1-R, 1-S, 1-T, 1-U, 1-Z, 1-AA, 1-BB, 1-CC, 1-EE, 1-FF, 1-GG, 1-HH, 1-II, 1-JJ, 1-KK 1-LL, 1-MM, 1-OO, 1-PP, 1-QQ, 1-RR, 1-SS, 1-TT, 1-AJ, 1-AK, 1-AL, 2-A, 2-C, 2-D, 2-E, 2-F, 2-G, 2-H, 2-I, 2-L, 3-A, 3-D, and 4-D. Example Nos. 1-NN and 1-UU demonstrated no binding activity and the remaining compounds were not determined.

Functional Assay

Swiss 3T3 cells expressing r-5HT_(2C), r-5HT_(2A), h-5HT_(2C) or h-5HT_(2A) receptors are seeded at a density of 12,500 cells/well in 384 well black/clear collagen-coated plates. Forty eight (48) hrs later the cells are loaded with the calcium sensitive dye, Fluo 4-AM (4 μM dissolved in DMSO containing pluronic acid) in serum free DMEM in the presence of probenicid (2.5 mM) for 75 minutes at 37° C. in a CO₂ incubator. Unincorporated dye is removed by washing 3 times with a HEPES-buffered saline containing probenicid (2.5 mM) using a Skatron™ cell washer (final volume 30 μL).

Plates are added to a fluorometric imaging plate reader (FLIPR 384 available from Molecular Devices Corporation) individually and fluorescence measurements are taken every 2 seconds over an 85 seconds period. Test compound additions are made simultaneously to all 384 wells after 20 seconds of baseline recording. Concentration-response curves are generated using Graphpad Prism™ (available from GraphPad Software, Inc., San Diego, Calif.) and agonist efficacies are generated as % of the response to 10 μM 5-HT (considered as 100%). Estimation of antagonist potencies (functional Kis) are generated by measuring inhibition of the test compound response to 5-HT (10 nM for 5-HT_(2C) and 50 nM for 5-HT_(2A)) and applying the Cheng Prusoff equation.

The functional data for the compounds listed in the Examples above utilizing the 5-HT_(2c) expressed NIH 3T3 cells is summarized below.

Example Nos. 1-A through 1-AL, 2-A through 2-L, 3-A through 3-D, 4-A through 4-D, and 5-A through 5-C acted as partial agonist having an EC₅₀ value in a range of 0.016 μM to 7.0 μM for the 5-HT_(2c) expressed cells with the exception of: (i) Example Nos. 1-PP and 2-F which acted as full antagonists, (ii) Example Nos. 2-D, 2-H, 1-NN and 1-QQ which demonstrated no 5-HT_(2c) functional activity at 10 μM and (iii) Example No. 1-ZZ which were not determined.

The functional data for the compounds listed in the Examples above utilizing the 5-HT_(2a) expressed NIH 3T3 cells is summarized below.

Example Nos. 1-A through 1-AL, 2-A through 2-L, 3-A through 3-D, 4-A through 4-D and 5-A through 5-C acted as partial agonist having an EC₅₀ value in a range of 0.16 μM to 7.6 μM with the exception of: (i) Example Nos. 1-S, 1-U, 1-Y, 1-FF, 1-GG, 1-HH, 1-II, 1-KK, 1-LL, 1-MM, 1-PP, 1-SS, 1-UU, i-VV, 1-WW, 1-XX, 1-YY, 1-AC, 1-Al, 2-E, 2-F, 2-G, 2-H, 2-I, 3-D, 4-A, 4-B, 4-C, 4-D, 5-A, 5-B, and 5-C which acted as full antagonists; (ii) Example Nos. 1-D, 1-F, 1-AG, 1-AK, 1-AL, 1-NN, and 1-QQ which demonstrated no functional activity at 10 μM; and (iii) Example 1-ZZ which was not determined.

Example No. 1-NN demonstrated no functional activity with either the 5-HT_(2a) or the 5-HT_(2c) expressed cells. Although the cis-isomer (Compound 1-NN) is not active, it does not necessarily suggest that the trans-isomer would not demonstrate functional activities.

Spontaneous Food Intake

Wistar rats are administered test compound either orally or subcutaneously in a 30% β-cyclodextrin vehicle 30 minutes prior to the onset of the dark cycle. Food intake is monitored using a computerized system that monitors the intake of individual animals. Food intake is monitored for at least 16 hours after administration of the test compound.

Sexual Dysfunction Example A Treatment of MED

Compounds of the present invention can be screened for effect of penile intracavernosal pressure (ICP) in the conscious male rat according to the methods described herein.

ICP Protocol: Intra cavernosal pressure (ICP) can be measured in the conscious rat by means of telemetric recording. A catheter is surgically implanted into the corpus cavernosum. The end of the catheter is linked to a device, which senses, processes, and transmits information digitally from within the animal. A receiver converts the radio-frequency signal from the implant to a digital pulse stream that is readable by a data collection system. The PC-based system collects telemetred data from the animal.

Surgery:—Induce and maintain general anaesthesia using 5% Isoflurane® in a carrier gas of 0.5 L/min oxygen and 1 L/min nitrous oxide to induce anaesthesia, reducing to 2% Isoflurane for maintenance anaesthesia. Administer 5 mg/kg sub cutaneously (s.c.) Carprofen (Rimadyl® Large Animal Injection, 50 mg/ml, Pfizer Animal Health) at induction of anaesthesia, at end of day of surgery and on the morning of first day post-surgery to minimise pain and discomfort.

Implantation of cornus cavernosal probe:—Shave the skin of the ventral abdomen and extend to include the area around the penis and ventral scrotum. Clean and disinfect the shaved area. Place the rat in dorsal recumbency. Make a mid-line incision from the external base of the penis, running caudally for approximately 2 cm. Locate and expose the internal structure of the penis and identify the corpus cavernosum. Make a mid-line laparotomy, approximately 4 cm in length to access the abdominal cavity. Pierce the abdominal wall via the caudal incision with a suitable trocar and cannula, taking care not to damage any internal organs. Place the implant body in the abdominal cavity with the catheter orientated caudally and pass the catheter tip through the body wall via the preplaced cannula. Implant used is model TA11PA-C40, 8 mm catheter, with modified 3 mm tip (Data Sciences International Inc.). Secure the implant body to the abdominal wall using non-absorbable sutures and partially close the abdominal incision. Reflect the tip of the penis cranially and retract the caudal incision to optimise the surgical field. Carefully isolate approximately 10 mm of the internal structure of the penis from the surrounding tissue. Carefully reflect the corpus spongiosum to one side to give access to the corpus cavernosum. Access the corpus cavernosum using a modified over-the-needle catheter to puncture the tunica. Introduce the catheter tip via the preplaced catheter and advance until fully inserted. Carefully remove the access catheter and apply a suitable tissue adhesive to the insertion site. Observe for leakage. Close the subcutaneous fat layer in the caudal incision before closing with an appropriate absorbable suture. Instil approximately 5 ml of warm saline through the abdominal incision and complete closure of the mid-line incision. Close the skin incision with an appropriate absorbable suture.

Postoperative care:—Measure food and water intake and monitor bodyweight daily for at least 7 days post surgery, then 2–3 times weekly. Give Lectade® (Pfizer Animal Health) in drinking water for 3 days post surgery. House rats singly, and transfer to reverse light/dark conditions 5 days post surgery. Named Veterinary Surgeon (or Deputy) to issue a certificate of fitness to continue 2 days post surgery. Start using rats experimentally 7 days post surgery.

Experimental Procedure:—Perform experiment in room with reverse light/dark conditions. On day of experiment, place rat in home cage on receiver pad (PhysioTel® Model RPC-1, Data Sciences International Inc.) and leave to acclimatise for approximately one hour. Ensure that the rat has food and water ad lib. Take baseline reading of intra cavernosal pressure (ICP) for approximately 5 minutes. Transfer the data via a floppy disk to an Excel spreadsheet. Inject the rat with compound subcutaneously or via the jugular vein catheter (JVC). If using the JVC, flush through with sterile saline after dosing and seal with a saline/glucose lock solution. The interval between administration of compound and ICP measurement will vary with the compound to be tested. An interval of 30–60 min post s.c. injection is a good guide. The test compounds were dissolved in 50% β-cyclodextrin in saline. They were administered at a dose of 5–10 mg/kg subcutaneously (s.c.). Apomorphine hydrochloride hemihydrate (Sigma A-4393) at 60 μg/kg s.c. was used as a positive control as it has pro-erectile properties. Record ICP over a 15 minute period, starting at 30 minutes post injection i.e. from 30 to 35 minutes and repeat for two further 15 minute periods commencing at 60 minutes post injection and 120 minutes post injection respectively. Record ICP for 15 minutes. A signal from the receiver pad feeds through to the Data Exchange Matrix® and hence to the software (Dataquest ART® acquisition system, Data Sciences International Inc.). Transfer the data via a floppy disk to an Excel spreadsheet for analysis.

Example B Compounds of Formula (I) in Combination with PDE5i for Treatment of MED

The effects of concomitant administration of a compound of the present invention in combination with a PDE5 inhibitor on the penile intracavernosal pressure (ICP) in an anaesthetised rabbit model of erection can be measured according to the following protocol.

Experimental Protocol

Male New Zealand rabbits (˜2.5 kg) are pre-medicated with a combination of Medetomidine (Domitor®) 0.5 ml/kg inramuscularly (i.m.), and Ketamine (Vetalar®) 0.25 ml/kg i.m. whilst maintaining oxygen intake via a face mask. The rabbits are tracheotomised using a Portex™ uncuffed endotracheal tube 3 ID (internal diameter), connected to ventilator and maintained at a ventilation rate of 30–40 breaths per minute, with an approximate tidal volume of 18–20 ml, and a maximum airway pressure of 10 cm H₂O. Anaesthesia was then switched to Isoflurane® and ventilation continued with O₂ at 2 liters/min. The right marginal ear vein was cannulated using a 23G or 24G catheter, and Lactated Ringer solution perfused at 0.5 ml/min. The rabbit was maintained at 3% Isoflurane during invasive surgery, dropping to 2% for maintenance anaesthesia. The left jugular vein was exposed, isolated and then cannulated with a PVC catheter (17 gauge/17G) for the infusion of drugs and the test compounds.

The left groin area of the rabbit was shaved and a vertical incision was made approximately 5 cm in length along the thigh. The femoral vein and artery were exposed, isolated and then cannulated with a PVC catheter (17G) for the infusion of drugs and compounds. Cannulation was repeated for the femoral artery, inserting the catheter to a depth of 10 cm to ensure that the catheter reached the abdominal aorta. This arterial catheter was linked to a Gould system to record blood pressure. Samples for blood gas analysis were also taken via the arterial catheter. Systolic and diastolic pressures were measured, and the mean arterial pressure calculated using the formula (diastolic×2+systolic)÷3. Heart rate was measured via the pulse oxymeter and Po-ne-mah data acquisition software system (Ponemah Physiology Platform, Gould Instrument Systems Inc).

A ventral midline incision was made into the abdominal cavity. The incision was about 5 cm in length just above the pubis. The fat and muscle was bluntly dissected away to reveal the hypogastric nerve which runs down the body cavity. It was essential to keep close to the side curve of the pubis wall in order to avoid damaging the femoral vein and artery which lie above the pubis. The sciatic and pelvic nerves lie deeper and were located after further dissection on the dorsal side of the rabbit. Once the sciatic nerve is identified, the pelvic nerve was easily located. The term pelvic nerve is loosely applied; anatomy books on the subject fail to identify the nerves in sufficient detail. However, stimulation of the nerve causes an increase in intracavernosal pressure and cavernosal blood flow, and innervation of the pelvic region. The pelvic nerve was freed away from surrounding tissue and a Harvard bipolar stimulating electrode was placed around the nerve. The nerve was slightly lifted to give some tension, then the electrode was secured in position. Approximately 1 ml of light paraffin oil was placed around the nerve and electrode. This acts as a protective lubricant to the nerve and prevents blood contamination of the electrode. The electrode was connected to a Grass S88 Stimulator. The pelvic nerve was stimulated using the following parameters:—5V, pulse width 0.5 ms, duration of stimulus 20 seconds with a frequency of 16 Hz. Reproducible responses were obtained when the nerve was stimulated every 15–20 minutes. Several stimulations using the above parameters were performed to establish a mean control response. The compound(s) to be tested were infused, via the jugular vein, using a Harvard 22 infusion pump allowing a continuous 15 minute stimulation cycle. The skin and connective tissue around the penis was removed to expose the penis. A catheter set (Insyte-W, Becton-Dickinson 20 Gauge 1.1×48 mm) was inserted through the tunica albica into the left corpus cavernosal space and the needle removed, leaving a flexible catheter. This catheter was linked via a pressure transducer (Ohmeda 5299-04) to a Gould system to record intracavernosal pressure (ICP). Once an intracavernosal pressure was established, the catheter was sealed in place using Vetbond (tissue adhesive, 3M). Heart rate was measured via the pulse oxymeter and Po-ne-mah data acquisition software system (Ponemah Physiology Platform, Gould Instrument Systems Inc).

Intracavernosal blood flow was recorded either as numbers directly from the Flowmeter using Po-ne-mah data acquisition software (Ponemah Physiology Platform, Gould Instrument Systems Inc), or indirectly from Gould chart recorder trace. Calibration was set at the beginning of the experiment (0–125 ml/min/100 g tissue).

All data are reported as mean ± s.e.m. (standard error of the mean). Significant changes were identified using Student's t-tests. The test compounds were dissolved in 50% β-cyclodextrin in saline. They were administered at a dose of 5–10 mg/kg subcutaneously (s.c.).

Using the protocol described hereinbefore beneficial effects on ICP can be demonstrated for the concomitant administration of a compound of the present invention (5–10 mg/kg s.c.) and a selective inhibitor of PDE5 (3-ethyl-5-{5-[4-ethylpiperzino)sulphonyl-2-propoxyphenyl}-2-(2-pyridylmethyl)-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimid in-7-one (as described in WO98/491066) (1 mg/kg i.v.(intravenously)). These studies suggest that there are a number of clinical benefits of concomitant administration of a PDE5 inhibitor and a compound of formula (I). Such benefits include increased efficacy and opportunities to treat MED subgroups that do not respond to other MED mono-therapies.

Example C Treatment of FSAD

Serotonin 5HT2C receptor agonists potentiate pelvic nerve-stimulated increases in female genital blood flow in the anaesthetised rabbit model of sexual arousal.

The normal sexual arousal response consists of a number of physiological responses that are observed during sexual excitement. These changes such as vaginal, labial and clitoral engorgement result from increases in genital blood flow. Engorgement leads to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and clitoral sensitivity.

Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of pre-, peri- and postmenopausal (±HRT) women. The primary consequence of FSAD is reduced genital engorgement or swelling which manifests itself as a lack of vaginal lubrication and a lack of pleasurable genital sensation. Secondary consequences include reduced sexual desire, pain during intercourse and difficulty in achieving orgasm. The most common cause of FSAD is decreased genital blood flow resulting in reduced vaginal, labial and clitoral engorgement (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of sildenafil on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int. J. Impot. Res., 10, S84–S90; Park, K., Goldstein, I., Andry, C., et al. (1997). Vasculogenic female sexual dysfunction: The hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency. Int. J. Impotence Res., 9, 27–37; Werbin, T., Salimpour, P., Berman, L., et al. (1999). Effect of sexual stimulation and age on genital blood flow in women with sexual stimulation. J. Urol., 161, 688).

As explained herein, the present invention provides a means for restoring or potentiating the normal sexual arousal response in women suffering from FSAD, by enhancing genital blood flow.

Method

Female New Zealand rabbits (˜2.5 kg) were pre-medicated with a combination of Medetomidine (Domitor®) 0.5 ml/kg intramuscularly (i.m.), and Ketamine (Vetalar®) 0.25 ml/kg i.m. whilst maintaining oxygen intake via a face mask. The rabbits were tracheotomised using a Portex™ uncuffed endotracheal tube 3 ID (internal diameter), connected to ventilator and maintained at a ventilation rate of 30–40 breaths per minute, with an approximate tidal volume of 18–20 ml, and a maximum airway pressure of 10 cm H₂O. Anaesthesia was then switched to Isoflurane® and ventilation continued with O₂ at 2 l/min. The right marginal ear vein was cannulated using a 23G or 24G catheter, and Lactated Ringer solution perfused at 0.5 ml/min. The rabbit was maintained at 3% Isoflurane® during invasive surgery, dropping to 2% for maintenance anaesthesia.

The left groin area of the rabbit was shaved and a vertical incision was made approximately 5 cm in length along the thigh. The femoral vein and artery were exposed, isolated and then cannulated with a PVC catheter (17G) for the infusion of drugs and compounds. Cannulation was repeated for the femoral artery, inserting the catheter to a depth of 10 cm to ensure that the catheter reached the abdominal aorta. This arterial catheter was linked to a Gould system to record blood pressure. Samples for blood gas analysis were also taken via the arterial catheter. Systolic and diastolic pressures were measured, and the mean arterial pressure calculated using the formula (diastolic×2+systolic)÷3. Heart rate was measured via the pulse oxymeter and Po-ne-mah data acquisition software system (Ponemah Physiology Platform, Gould Instrument Systems Inc).

A ventral midline incision was made into the abdominal cavity. The incision was about 5 cm in length just above the pubis. The fat and muscle was bluntly dissected away to reveal the hypogastric nerve which runs down the body cavity. It was essential to keep close to the side curve of the pubis wall in order to avoid damaging the femoral vein and artery, which lie above the pubis. The sciatic and pelvic nerves lie deeper and were located after further dissection on the dorsal side of the rabbit. Once the sciatic nerve is identified, the pelvic nerve was easily located. The term pelvic nerve is loosely applied; anatomy books on the subject fail to identify the nerves in sufficient detail. However, stimulation of the nerve causes an increase in vaginal and clitoral blood flow, and innervation of the pelvic region. The pelvic nerve was freed away from surrounding tissue and a Harvard bipolar stimulating electrode was placed around the nerve. The nerve was slightly lifted to give some tension, then the electrode was secured in position. Approximately 1 ml of light paraffin oil was placed around the nerve and electrode. This acts as a protective lubricant to the nerve and prevents blood contamination of the electrode. The electrode was connected to a Grass S88 Stimulator. The pelvic nerve was stimulated using the following parameters:—5V, pulse width 0.5 ms, duration of stimulus 10 seconds and a frequency range of 2 to 16 Hz. Reproducible responses were obtained when the nerve was stimulated every 15–20 minutes. A frequency response curve was determined at the start of each experiment in order to determine the optimum frequency to use as a sub-maximal response, normally 4 Hz. A ventral midline incision was made, at the caudal end of the pubis, to expose the pubic area. Connective tissue was removed to expose the tunica of the clitoris, ensuring that the wall was free from small blood vessels. The external vaginal wall was also exposed by removing any connective tissue. One laser Doppler flow probe was inserted 3 cm into the vagina, so that half the probe shaft was still visible. A second probe was positioned so that it lay just above the external clitoral wall. The position of these probes was then adjusted until a signal was obtained. A second probe was placed just above the surface of a blood vessel on the external vaginal wall. Both probes were clamped in position.

Test Compounds

8,9-dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-one, which corresponds to Compound 75 of Chaki and Nakazato—Expert Opin. Ther. Patents (2001), 11(11):1677–1692 (see Section 3.9–5HT_(2c) on page 1687 and FIG. 7 on page 1686), or Compound (6) of Isaac-Drugs of the Future (2001), 26(4):383–393 (see FIG. 2 on page 385).

8,9-dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-one was dissolved in 50% β-cyclodextrin in saline. It was administered at a dose of 5 mg/kg subcutaneously (s.c.).

Data Recordal

Vaginal and clitoral blood flow was recorded either as numbers directly from the Flowmeter using Po-ne-mah data acquisition software (Ponemah Physiology Platform, Gould Instrument Systems Inc), or indirectly from Gould chart recorder trace. Calibration was set at the beginning of the experiment (0–125 ml/min/100 g tissue). All data are reported as mean ÷ standard error of the mean (s.e.m.). Significant changes were identified using Student's t-tests.

Results

The serotonin 5HT2C receptor agonist (8,9-dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-one; 5 mg/kg s.c.) acts as a potent enhancer of pelvic-nerve stimulated (PNS) increases in vaginal and clitoral blood flow in the anaesthetised rabbit (see Table 8 below). The potentiation was significant 30mins after s.c. dosing and remained elevated for circa 1 hr. The 5HT2c agonist had no effect on basal genital blood flow in the absence of PNS (see Table 8 below). This reinforces our view that a 5HT2c receptor agonist will enhance the arousal response by potentiating the mechanism(s) that control sexual arousal/genital blood flow, thereby treating FSAD, and will not induce arousal in the absence of sexual stimulation. Since these agents also enhance clitoral blood flow it is likely that they will be effective in the treatment of orgasmic disorders.

Table 8 below illustrates that 8,9-dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-one (5 mg/kg s.c.) potentiates pelvic nerve stimulated increases in genital blood flow circa 35% after subcutaneous administration in the anaesthetised rabbit model of sexual arousal.

TABLE 8 Time after injection of Pelvic nerve Compound 8,9-dichloro- stimulated Compound- 2,3,4,4a-terahydro-1H- Unstimulated increases in induced pyrazino[1,2- vaginal blood flow vaginal blood flow potentiation of a]quinoxalin-5(6H)-one (Laser Doppler (Laser Doppler stimulated vaginal (min) units) units) blood flow Pre dose 148 +/− 6 241 +/− 10 — 15 185 292 21 30 162 325 34 45 150 295 22 60 127 325 34 75 137 252  4 90 132 247  2 

1. A compound of Formula (IC)

wherein X and Y are CR and Z is N, or X is N and Y and Z are CR, where R for each occurrence is hydrogen, halogen, (C₁–C₄)alkyl, amino, or (C₁–C₄)alkylamino; W is oxy, thio, amino, (C₁–C₄)alkylamino, or acetylamino; Q is a heteroaryl group selected from the group consisting of pyridin-2-yl, pyridin-3-yl, furan-3-yl, furan-2-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, pyrrol-2-yl, pyrrol-3-yl, pyrazol-3-yl, quinolin-2-yl, quinolin-3-yl, isoquinolin-3-yl, benzofuran-2-yl, benzofuran-3-yl, isobenzofuran-3-yl, benzothiophen-2-yl, benzothiophen-3-yl, indol-2-yl, indol-3-yl, 2H-imidazol-2-yl, oxazol-2-yl, isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-triazol-3-yl, and 1,2,4-oxathiazol-3-yl, where said heteroaryl group is optionally substituted with one to three substituents independently selected from halo, (C₁–C₄)alkyl or (C₁–C₄)alkyoxy; R^(2a) and R^(2b) are each independently hydrogen, (C₁–C₄)alkyl, or partially or fully saturated (C₃–C₆)cycloalkyl; R^(3a) and R^(3b) are each independently hydrogen, (C₁–C₄)alkyl, or (C₁–C₄)alkyl substituted with hydroxy, fluoro, or (C₁–C₄)alkoxy; R⁴ is hydrogen, hydroxy, (C₁–C₄)alkyl, (C₁–C₄)alkyl substituted with hydroxy or cyano, (C₁–C₄)alkylcarbonyl, (C₁–C₄)alkoxy, (C₁–C₄)alkoxy-carbonyl, or (C₃–C₄)alkenyl; a nitrogen oxide thereof, an ester or amide prodrug of said compound or said nitrogen oxide; a pharmaceutically acceptable salt of said compound, said nitrogen oxide, or said prodrug, or a pharmaceutically acceptable solvate or hydrate of said compound, said nitrogen oxide, said prodrug, or said salt.
 2. The compound of claim 1 selected from the group consisting of 4-piperazin-1-yl-2-(pyridin-2-ylmethoxy)-pyrimidine, 2-(6-methyl-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine, and 2-(6-chloro-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine; a nitrogen oxide thereof, an ester or amide prodrug of said compound or said nitrogen oxide; a pharmaceutically acceptable salt of said compound, said nitrogen oxide, or said prodrug, or a pharmaceutically acceptable solvate or hydrate of said compound, said nitrogen oxide, said prodrug, or said salt.
 3. The compound of claim 1 selected from the group consisting of 2-(6-methyl-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine and 2-(6-chloro-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine; a nitrogen oxide thereof, an ester or amide prodrug of said compound or said nitrogen oxide; a pharmaceutically acceptable salt of said compound, said nitrogen oxide, or said prodrug, or a pharmaceutically acceptable solvate or hydrate of said compound, said nitrogen oxide, said prodrug or said salt.
 4. A method for treating obesity in an animal comprising the step of administering to said animal a therapeutically effective amount of a compound of claim 1, a nitrogen oxide thereof, an ester or amide prodrug of said compound or said nitrogen oxide; a pharmaceutically acceptable salt of said compound, said nitrogen oxide, or said prodrug, or a pharmaceutically acceptable solvate or hydrate of said compound, said nitrogen oxide, said prodrug or said salt.
 5. A method for reducing calorie intake in an animal comprising the step of administering to said animal a therapeutically effective amount of a compound of claim 1, a nitrogen oxide thereof, an ester or amide prodrug of said compound or said nitrogen oxide; a pharmaceutically acceptable salt of said compound, said nitrogen oxide, or said prodrug, or a pharmaceutically acceptable solvate or hydrate of said compound, said nitrogen oxide, said prodrug or said salt. 